Invitae (NVTAQ) 10-K 28 Feb 23 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 24, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36847
Entity Registrant Name	Invitae Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1701898
Entity Address, Address Line One	1400 16th Street
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94103
City Area Code	415
Local Phone Number	374-7782
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	NVTA
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 569.8
Entity Common Stock, Shares Outstanding		246,235,501
Documents Incorporated by Reference	Items 10 (as to directors and Section 16(a) Beneficial Ownership Reporting Compliance), 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K incorporate by reference information from the registrant’s proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for the registrant’s 2023 Annual Meeting of Stockholders .
Entity Central Index Key	0001501134
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Auditor Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	San Mateo, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 257,489	$ 923,250
Marketable securities	289,611	122,121
Accounts receivable	96,148	66,227
Inventory	30,386	33,516
Prepaid expenses and other current assets	19,496	33,691
Total current assets	693,130	1,178,805
Property and equipment, net	108,723	114,714
Operating lease assets	106,563	121,169
Restricted cash	10,030	10,275
Intangible assets, net	1,012,549	1,187,994
Goodwill	0	2,283,059
Other assets	23,121	23,551
Total assets	1,954,116	4,919,567
Current liabilities:
Accounts payable	13,984	21,127
Accrued liabilities	74,388	106,453
Operating lease obligations	14,600	12,359
Finance lease obligations	5,121	4,156
Total current liabilities	108,093	144,095
Operating lease obligations, net of current portion	134,386	124,369
Finance lease obligations, net of current portion	3,780	5,683
Debt	122,333	113,391
Convertible senior notes, net	1,470,783	1,464,138
Deferred tax liability	8,130	51,696
Other long-term liabilities	4,775	37,797
Total liabilities	1,852,280	1,941,169
Commitments and contingencies (Note 8)
Preferred stock, $0.0001 par value: 20,000 shares authorized; nil shares issued and outstanding as of December 31, 2022 and 2021, respectively	0	0
Stockholders’ equity:
Common stock, $0.0001 par value: 600,000 and 400,000 shares authorized; 245,562 and 228,116 shares issued and outstanding as of December 31, 2022 and 2021, respectively	25	23
Accumulated other comprehensive loss	(80)	(7)
Additional paid-in capital	4,931,032	4,701,230
Accumulated deficit	(4,829,141)	(1,722,848)
Total stockholders’ equity	101,836	2,978,398
Total liabilities and stockholders’ equity	$ 1,954,116	$ 4,919,567

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, issued (in shares)	0	0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	20,000,000	20,000,000
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	600,000,000	400,000,000
Common stock, issued (in shares)	245,562,000	228,116,000
Common stock, outstanding (in shares)	245,562,000	228,116,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 516,303	$ 460,449	$ 279,598
Operating expenses:
Cost of revenue	417,256	348,669	198,275
Research and development	402,088	416,087	240,605
Selling and marketing	218,881	225,910	168,317
General and administrative	192,314	248,070	270,029
Goodwill and IPR&D impairment	2,313,047	0	0
Restructuring and other costs	140,331	0	0
Gain on sale of RUO kit assets	(47,354)	0	0
Change in fair value of contingent consideration	(1,850)	(386,646)	54,544
Total operating expenses	3,634,713	852,090	931,770
Loss from operations	(3,118,410)	(391,641)	(652,172)
Other income (expense), net:
Change in fair value of acquisition-related liabilities	15,906	25,196	(37,527)
Other income, net	8,054	482	5,195
Total other income (expense), net	23,960	25,678	(32,332)
Interest expense	(56,747)	(49,900)	(29,766)
Net loss before taxes	(3,151,197)	(415,863)	(714,270)
Income tax benefit	44,904	36,857	112,100
Net loss	$ (3,106,293)	$ (379,006)	$ (602,170)
Net loss per share, basic (in dollars per share)	$ (13.18)	$ (1.80)	$ (4.47)
Net loss per share, diluted (in dollars per share)	$ (13.18)	$ (1.80)	$ (4.47)
Shares used in computing net loss per share, basic (in shares)	235,676,000	210,946,000	134,587,000
Shares used in computing net loss per share, diluted (in shares)	235,676,000	210,946,000	134,587,000
Test revenue
Revenue:
Total revenue	$ 500,560	$ 444,072	$ 272,310
Data/services
Revenue:
Total revenue	$ 15,743	$ 16,377	$ 7,288

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,106,293)	$ (379,006)	$ (602,170)
Other comprehensive (loss) income:
Unrealized (loss) income on available-for-sale marketable securities, net of tax	(73)	(8)	10
Comprehensive loss	$ (3,106,366)	$ (379,014)	$ (602,160)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock:	Accumulated other comprehensive (loss) income:	Additional paid-in capital:	Additional paid-in capital: Revision of prior period, adjustment	Accumulated deficit:	Accumulated deficit: Cumulative effect of accounting change
Increase (Decrease) in Stockholders' Deficit
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Balance, beginning of period at Dec. 31, 2019		$ 10	$ (9)	$ 1,138,316		$ (758,677)
Increase (Decrease) in Stockholders' Deficit
Unrealized (loss) income on available-for-sale marketable securities, net of tax	$ 10		10
Common stock issued in private placement, net				263,628
Common stock issued in connection with public offering, net		9		263,685
Common stock issued on exercise of stock options, net				10,730
Common stock issued pursuant to exercises of warrants				974
Common stock issued pursuant to employee stock purchase plan				8,871
Common stock and equity awards issued pursuant to acquisitions				1,524,227
Warrants issued pursuant to loan agreement				27,000
Stock-based compensation expense				110,076
Net loss	(602,170)					(602,170)
Balance, end of period at Dec. 31, 2020	1,976,293	19	1	3,337,120	$ 0	(1,360,847)	$ 0
Balance, end of period (Reclassification of stock payable liabilities) at Dec. 31, 2020					(10,387)
Increase (Decrease) in Stockholders' Deficit
Unrealized (loss) income on available-for-sale marketable securities, net of tax	(8)		(8)
Common stock issued in private placement, net				0
Common stock issued in connection with public offering, net		4		434,263
Common stock issued on exercise of stock options, net				8,984
Common stock issued pursuant to exercises of warrants				1,242
Common stock issued pursuant to employee stock purchase plan				13,550
Common stock and equity awards issued pursuant to acquisitions				805,124
Warrants issued pursuant to loan agreement				0
Stock-based compensation expense				176,435
Net loss	(379,006)					(379,006)
Balance, end of period at Dec. 31, 2021	2,978,398	23	(7)	4,701,230	(75,488)	(1,722,848)	17,005
Balance, end of period (Reclassification of stock payable liabilities) at Dec. 31, 2021					0
Increase (Decrease) in Stockholders' Deficit
Unrealized (loss) income on available-for-sale marketable securities, net of tax	(73)		(73)
Common stock issued in private placement, net				0
Common stock issued in connection with public offering, net		2		9,658
Common stock issued on exercise of stock options, net				643
Common stock issued pursuant to exercises of warrants				0
Common stock issued pursuant to employee stock purchase plan				7,513
Common stock and equity awards issued pursuant to acquisitions				15,027
Warrants issued pursuant to loan agreement				0
Stock-based compensation expense				196,961
Net loss	(3,106,293)					(3,106,293)
Balance, end of period at Dec. 31, 2022	$ 101,836	$ 25	$ (80)	$ 4,931,032	0	$ (4,829,141)	$ 0
Balance, end of period (Reclassification of stock payable liabilities) at Dec. 31, 2022					$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (3,106,293)	$ (379,006)	$ (602,170)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill and IPR&D impairment	2,313,047	0	0
Impairments and losses on disposals of long-lived assets	60,507	0	0
Gain on sale of RUO kit assets	(47,354)	0	0
Depreciation and amortization	142,071	80,472	39,050
Stock-based compensation	199,304	180,075	158,747
Amortization of debt discount and issuance costs	15,587	14,226	17,204
Remeasurements of liabilities associated with business combinations	(17,756)	(411,842)	92,348
Benefit from income taxes	(44,904)	(36,857)	(112,100)
Post-combination expense for acceleration of unvested equity and deferred stock compensation	8,428	9,530	91,021
Amortization of premiums and discounts on investment securities	(1,515)	6,221	1,236
Non-cash lease expense	10,240	3,496	777
Other	1,018	1,487	(588)
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable	(29,921)	(16,696)	(2,814)
Inventory	3,130	(1,486)	(7,832)
Prepaid expenses and other current assets	14,195	(14,563)	(2,010)
Other assets	3,124	(3,274)	895
Accounts payable	(2,465)	(9,258)	10,186
Accrued expenses and other long-term liabilities	(13,404)	17,660	17,548
Net cash used in operating activities	(492,961)	(559,815)	(298,502)
Cash flows from investing activities:
Purchases of marketable securities	(892,361)	(325,957)	(280,258)
Proceeds from sales of marketable securities	0	0	12,832
Proceeds from maturities of marketable securities	726,313	425,293	277,487
Acquisition of businesses, net of cash acquired	0	(247,396)	(383,753)
Proceeds from sale of RUO kit assets	44,554	0	0
Purchases of property and equipment	(53,309)	(54,720)	(22,865)
Other	0	(1,300)	(4,026)
Net cash used in investing activities	(174,803)	(204,080)	(400,583)
Cash flows from financing activities:
Proceeds from public offerings of common stock, net	9,658	434,263	263,688
Proceeds from issuance of common stock	8,157	23,767	284,203
Proceeds from issuance of convertible senior notes, net	0	1,116,427	0
Proceeds from issuance of debt, net	0	0	129,214
Finance lease principal payments	(5,410)	(3,759)	(2,655)
Settlement of acquisition obligations	(10,647)	(4,758)	(1,457)
Net cash provided by financing activities	1,758	1,565,940	672,993
Net (decrease) increase in cash, cash equivalents and restricted cash	(666,006)	802,045	(26,092)
Cash, cash equivalents and restricted cash at beginning of period	933,525	131,480	157,572
Cash, cash equivalents and restricted cash at end of period	267,519	933,525	131,480
Supplemental cash flow information:
Interest paid	40,504	31,400	12,130
Supplemental cash flow information of non-cash investing and financing activities:
Consideration receivable for sale of RUO kit assets	3,000	0	0
Equipment acquired through finance leases	4,472	8,224	4,463
Purchases of property and equipment in accounts payable and accrued liabilities	820	13,222	1,869
Warrants issued pursuant to debt agreement	0	0	27,000
Common stock issued for acquisition of businesses	6,600	802,073	1,157,958
Consideration payable for acquisition of businesses	0	46,649	940,829
Operating lease assets obtained in exchange for lease obligations, net	$ 4,495	$ 88,777	$ 14,058

Organization and description of

Organization and description of business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and description of business	Organization and description of business Invitae Corporation ("Invitae," “the Company," "we," "us," and "our") was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and we changed our name to Invitae Corporation in 2012. We offer high-quality, comprehensive, affordable genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. To augment our portfolio and realize our mission, we have previously acquired multiple assets and businesses that further expanded our test menu and suite of digital health and data offerings and accelerated our entry into key genomics markets. We are building a platform to harness genetics to diagnose more patients correctly and earlier, while enabling our partners to bring therapies to market faster. Invitae operates in one segment. Strategic realignment On July 18, 2022, the Company initiated a strategic realignment of our operations and began implementing cost reduction programs to prioritize its core genetic testing and digital health and data platforms, which was approved by the board of directors of the Company on July 16, 2022. See Note 11, "Restructuring and other costs" for additional information regarding our strategic realignment.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Principles of consolidation Our consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis. Significant estimates and assumptions made by management include the determination of: • revenue recognition; • inventory adjustments; • the fair value of assets and liabilities associated with business combinations; • the impairment assessment of goodwill and intangible assets; • the recoverability of long-lived assets; • our incremental borrowing rates used to calculate our lease balances; • stock-based compensation expense and the fair value of awards and warrants issued; and • income tax uncertainties. Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, restricted cash, marketable securities and accounts receivable. Our cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits. Significant customers are those that represent 10% or more of our total revenue for each year presented in the consolidated statements of operations. Our revenue and accounts receivable from significant customers as a percentage of our total revenue and total accounts receivable was as follows: Revenue Accounts receivable Year Ended December 31, December 31, 2022 2021 2020 2022 2021 Medicare 14 % 15 % 19 % 16 % * * less than 10% Cash, cash equivalents, and restricted cash We consider all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds, U.S. Treasury notes and government agency securities. Restricted cash consists primarily of money market funds that secure irrevocable standby letters of credit that serve as collateral for security deposits for our facility leases. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 257,489 $ 923,250 Restricted cash 10,030 10,275 Total cash, cash equivalents and restricted cash $ 267,519 $ 933,525 Marketable securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities one year or less at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and impairments, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in other income (expense), net. For marketable securities in an unrealized loss position, we assess our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the security’s amortized cost basis is written down to fair value through other income (expense), net. Accounts receivable We receive payment from patients, biopharmaceutical partners, third-party payers and other business-to-business customers. See Note 3, "Revenue, accounts receivable and deferred revenue" for further information. Allowances for losses on certain financial assets We assess our accounts receivables for expected credit losses at each reporting period by disaggregating by payer type and further by portfolios of customers with similar characteristics, such as customer type and geographic location. We then review each portfolio for expected credit losses based on historical payment trends as well as forward looking data and current economic trends. If a credit loss is determined, we record a reduction to our accounts receivable balance with a corresponding general and administrative expense. We review available-for-sale debt securities in an unrealized loss positions at each balance sheet date and assess whether such unrealized loss positions are credit-related. Our expected loss allowance methodology for these securities is developed by reviewing the extent of the unrealized loss, the issuers’ credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers’ current status and financial condition. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income (expense), net. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss. Deferred revenue We record a contract liability when cash payments are received or due in advance of our performance related to one or more performance obligations. See Note 3, "Revenue, accounts receivable and deferred revenue" for further information. Inventory Our inventory consists of raw materials, work in progress, and finished goods, which are stated at the lower of cost or net realizable value on a first-in, first-out basis. We periodically analyze our inventory levels and expiration dates, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its net realizable value, and inventory in excess of expected sales requirements as cost of revenue. We record an allowance for obsolete inventory using an estimate based on historical trends and evaluation of near-term expirations. Business combinations We apply ASC 805, Business Combinations , which requires recognition of assets acquired, liabilities assumed, and contingent consideration at their fair value on the acquisition date with subsequent changes recognized in earnings; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination and expensed as incurred; requires in-process research and development to be capitalized at fair value as an indefinite-lived intangible asset until completion or abandonment; and requires that changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period be recognized as a component of provision for taxes. We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. We base the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by our management, which consider our estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity , we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We remeasure this liability each reporting period and record changes in the fair value in change in fair value of contingent consideration in our consolidated statements of operations. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in our operating results from the date of acquisition. Asset acquisitions In circumstances where substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the asset is not considered a business and we account for the transaction as an asset acquisition. We recognize the assets acquired based on their relative fair value, which generally includes the transaction costs of the asset acquisition, and no gain or loss is recognized unless the fair value of noncash assets given as consideration differs from the assets’ carrying amounts. The form of consideration transferred may be cash, liabilities incurred, or equity interests issued. Intangible assets Amortizable intangible assets include trade names, non-compete agreements, patent licensing agreements, favorable leases, developed technology, customer relationships, and rights to develop new technology acquired as part of business combinations. Customer relationships acquired through our business combinations in 2017 are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five ranging from five Property, Plant and Equipment. Goodwill In accordance with ASC 350, Intangibles-Goodwill and Other , our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, we perform annual impairment reviews of our goodwill balance during the fourth fiscal quarter or more frequently if business factors indicate. In testing for impairment, we compare the fair value of our reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, we will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit. In-process research and development Intangible assets related to IPR&D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. During the fourth quarter and if business factors indicate more frequently, we perform an assessment of the qualitative factors affecting the fair value of our IPR&D projects. If the fair value exceeds the carrying value, there is no impairment. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of an asset to its carrying value, without consideration of any recoverability test. Leases Under ASC 842, Leases , we determine if an arrangement is a lease at inception. Operating leases are included in operating lease assets and operating lease obligations in our consolidated balance sheets. Finance leases are included in other assets and finance lease obligations in our consolidated balance sheets. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. We generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The operating lease asset also includes any lease payments made and is adjusted for lease incentives. Our lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that we will exercise that option. Leases with terms of 12 months or less are not recorded on our balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. We account for the lease and non-lease components of our operating right-of-use assets as a single lease component. Property and equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Manufacturing and Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life Long-lived assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. During the year ended December 31, 2022, we recognized losses on disposal of property and equipment of $19.1 million, which are recorded in restructuring and other costs in the consolidated statements of operations. See Note 5, "Goodwill and intangible assets" under the heading "Impairment assessment" and Note 6, "Balance sheet components" under the heading "Property and equipment, net" for additional information. We did not incur any losses on disposal of property and equipment during the years ended December 31, 2021 and 2020, respectively. Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, finance lease liabilities, and liabilities associated with business combinations. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our finance lease liabilities approximates their fair values. Liabilities associated with business combinations are recorded at their estimated fair value. Revenue recognition We recognize revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. We utilize the following practical expedients and exemptions: • Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year or less, and • No adjustments to promised consideration were made for financing as we expect, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less. Test revenue Test revenue is comprised of testing services and sales of distributed precision oncology products. The majority of our test revenue is generated from genetic testing, in addition to somatic testing for therapy selection and personalized cancer monitoring. These testing services provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions or contractual agreements, and we often enter into contracts with insurance companies and institution customers that include pricing provisions under which such tests are billed. Billing terms are generally net 30 to 60 days. While the transaction price of diagnostic tests is originally established either via contract or pursuant to our standard list price, we often provide concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which we will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed each reporting period and updated as necessary. We look to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with the service portion of our diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on our web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a 30-day period. We also generated test revenue through the sale of our distributed precision oncology products, which is comprised primarily of sales of our RUO kit and IVD product offerings for therapy selection. We recognized revenue on these sales once shipment had occurred. Product sales were recorded net of discounts and other deductions. Billing terms were generally net 30 days. As part of the strategic realignment, we exited these product offerings in fiscal year 2022. See Note 4, "Business combinations and dispositions" for additional information on the disposition of the RUO kit assets. See Note 5, "Goodwill and intangible assets" for additional information on the exit of the IVD product offering. Shipping and handling fees billed to customers are recorded as revenue in the consolidated statements of operations. The associated shipping and handling costs are recorded as cost of revenue. Other revenue Other revenue is primarily generated from collaboration agreements and genome network contracts as well as pharma development services provided to biopharmaceutical companies related to companion diagnostic development. We enter into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the data and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods. Amounts due under collaboration and genome network agreements are typically billable on net 30-day terms. Contracts for companion diagnostic development consisted primarily of milestone-based payments along with annual fees and marked-up pass-through costs. The arrangements were treated as short-term contracts for revenue recognition purposes because they allow termination of the agreements by the customers with 30 to 120 days’ written notice without a termination penalty. Upon termination, customers were required to pay for the proportion of services provided under milestones that were in progress. We recognized revenue in an amount that reflected the consideration which we expect to receive in exchange for those goods or services. We recognized revenue as services are provided based on the progress made toward achieving the performance obligation, utilizing input methods, including labor hours expended and tests processed, that measure our progress toward the achievement of the milestone. Cost of revenue Cost of revenue reflects the aggregate costs incurred in delivering our products and services and includes expenses for materials and supplies, personnel-related costs, freight, costs for lab services and clinical trial support, equipment and infrastructure expenses and allocated overhead including rent, information technology costs, equipment depreciation, amortization of acquired intangibles, and utilities. License Agreements We have entered and may continue to enter into license agreements to access and utilize certain technology. We evaluate if the license agreement results in the acquisition of an asset or a business and then determine if the acquired asset has the ability to generate revenues or is subject to regulatory approval. When regulatory approval is not required, we record the license as an asset and amortize it over the estimated economic life. When regulatory approval is required, we record the amount paid as a research and development expense. Advertising Advertising expenses are expensed as incurred. We incurred advertising expenses of $5.9 million, $20.2 million and $11.4 million during the years ended December 31, 2022, 2021 and 2020, respectively. Stock-based compensation We measure stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognize the compensation expense over the requisite service period. We use the Black-Scholes option-pricing model to estimate the fair value of stock option awards and ESPP purchases. The fair value of RSU awards with time-based vesting terms is based on the grant date share price. We grant PRSU awards to certain employees, which vest upon the achievement of certain performance conditions subject to the employees’ continued service relationship with us. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. We recognize such compensation expense on an accelerated vesting method. Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We account for stock issued in connection with business combinations based on the fair value on the date of issuance. Restructuring and other costs Restructuring and other costs are comprised of employee severance and benefits, asset impairments and losses on asset disposals, and other costs primarily related to implementing our strategic realignment. Employee separation costs are comprised of severance, other termination benefit costs, and stock-based compensation expense for the acceleration of stock awards related to workforce reductions. We recognize costs and liabilities associated with exit and disposal activities in accordance with ASC 420, Exit and Disposal Cost Obligations, and other costs and liabilities associated with postemployment nonretirement benefits in accordance with ASC 712, Postemployment Nonretirement Benefits . Liabilities are based on the estimate of fair value in the period the liabilities are incurred, with subsequent changes to the liability recognized as adjustments in the period of change. We recognize losses on asset disposals in accordance with ASC 360, Impairment or Disposal of Long-Lived Assets . Restructuring and other costs are recognized as an operating expense within the consolidated statements of operations and the related liabilities are recorded within accrued liabilities in the consolidated balance sheets. Income taxes We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Significant judgment is required in determining the net valuation allowance which includes our evaluation of all available evidence including past operating results, estimates on future taxable income and acquisition-related tax assets and liabilities. We historically established a full valuation allowance against our deferred tax assets due to the uncertainty surrounding realization of such assets. Comprehensive loss Comprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. Our other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities. Net loss per share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, shares of common stock pursuant to ESPP, common stock issuable in connection with our convertible senior notes, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented. Recent accounting pronouncements We evaluate all Accounting Standards Updates ("ASUs") issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our consolidated financial statements. Recently issued accounting pronouncements not yet adopted In October 2021, the FASB issued ASU 2021-08, Business Combinations ("Topic 805"): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments of this ASU require entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to all business combinations occurring after the date of adoption. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our consolidated financial statements. Recently adopted accounting pronouncements In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity , which simplifies the accounting for certain convertible instruments, amends the guidance on derivative scope exceptions for contracts in an entity's own equity, and modifies the guidance on diluted earnings per share calculations as a result of these changes. This new standard is effective for our interim and annual periods beginning January 1, 2022, with early adoption permitted. We elected to adopt the amendments on a modified retrospective basis effective January 1, 2021, which required a cumulative-effect adjustment to retained earnings. The cumulative-effect adjustment resulted in a decrease in accumulated deficit of $17.0 million related to the reversal of the equity component and associated issuance costs as well as adjustment of the related amortization costs of our convertible senior notes due 2024. Reporting periods beginning on or after January 1, 2021 are presented under this new guidance while prior periods have not been adjusted and continue to be reported in accordance with our historic accounting under U.S. GAAP. See Note 8, "Commitments and contingencies" for additional information about our convertible senior notes.

Revenue, accounts receivable an

Revenue, accounts receivable and deferred revenue	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue, accounts receivable and deferred revenue	Revenue, accounts receivable and deferred revenue During the year ended December 31, 2022, the Company changed its presentation of disaggregated revenue from revenue by services and products to clinical category of our product offerings to better align with our operations. The change had no impact on the timing of revenue recognition and had no effect on our reported results of operations. Presentation of disaggregated revenue by services and products in prior periods have been modified to conform to the current period presentation. Test revenue is generated from sales of diagnostic tests and precision oncology products to two groups of customers: patients, consideration for which may be paid directly by the patients or by the patients' insurance carriers, and institutions (e.g., hospitals, clinics, medical centers and biopharmaceutical partners). Amounts billed and collected, and the timing of collections, vary based on the type of customer and the corresponding payer, including the patients' insurance carriers that are paying on behalf of the customer. Data and service revenue consists principally of revenue recognized for the performance of activities as outlined in biopharmaceutical development contracts and other collaboration and genome network agreements. The following tables present revenue disaggregated by customer and product offering by disease category (in thousands): Patient Institution Year Ended December 31, 2022 Insurance Direct Product: Oncology $ 208,239 $ 10,327 $ 89,922 $ 308,488 Women's health 70,571 18,082 7,127 95,780 Rare diseases 31,527 10,044 24,462 66,033 Data/services — — 46,002 46,002 Total revenue $ 310,337 $ 38,453 $ 167,513 $ 516,303 Patient Institution Year Ended December 31, 2021 Insurance Direct Product: Oncology $ 200,456 $ 11,341 $ 70,439 $ 282,236 Women's health 52,759 21,316 8,696 82,771 Rare diseases 23,701 9,011 24,504 57,216 Data/services — — 38,226 38,226 Total revenue $ 276,916 $ 41,668 $ 141,865 $ 460,449 Patient Institution Year Ended December 31, 2020 Insurance Direct Product: Oncology $ 142,552 $ 6,479 $ 25,868 $ 174,899 Women's health 25,050 12,684 6,404 44,138 Rare diseases 13,424 4,809 16,320 34,553 Data/services — — 26,008 26,008 Total revenue $ 181,026 $ 23,972 $ 74,600 $ 279,598 We recognize revenue related to billings based on estimates of the amount that will ultimately be realized. Cash collections for certain tests delivered may differ from rates originally estimated. In subsequent periods, we update our estimate of the amounts recognized for previously delivered tests resulting in the following increases to revenue and decreases to our net loss from operations and basic and diluted net loss per share (in millions, except per share data): Year Ended December 31, 2022 2021 2020 Revenue $ 2.8 $ 13.5 $ 4.4 Loss from operations $ (2.8) $ (13.5) $ (4.4) Net loss per share, basic and diluted $ (0.01) $ (0.06) $ (0.03) The increase in revenue from previously delivered tests for the years ended December 31, 2022, 2021 and 2020 was primarily due to higher average revenue per test across all test categories when compared to initial estimates. Impact of COVID-19 We expect the COVID-19 pandemic may continue to impact our business. We have reviewed and adjusted, when necessary, for the impact of COVID-19 on our estimates related to revenue recognition and expected credit losses. In March 2020, the CARES Act was signed into law as a stimulus bill intended to bolster the economy, among other things, and provide assistance to qualifying businesses and individuals. The CARES Act included an infusion of funds into the healthcare system. In April 2020, we received $3.8 million as a part of this initiative, and in January 2021, we received an additional $2.3 million. These payments were recognized as other income (expense), net in our consolidated statements of operations during the periods received. At this time, we are not certain of the availability, extent or impact of any future relief provided under the CARES Act. Accounts receivable The majority of our accounts receivable represents amounts billed to customers for test and data and service activities, and the estimated amounts to be collected from patients' insurance carriers for test services. We record a contract asset for services delivered under certain biopharmaceutical contracts, which are unbilled as of the end of the period. The contract receivable was $1.3 million and $4.3 million as of December 31, 2022 and 2021, respectively, and was included in prepaid expenses and other current assets in the consolidated balance sheets. Deferred revenue We record a contract liability when cash payments are received or due in advance of our performance related to one or more performance obligations. The deferred revenue balance primarily consists of advanced billings for biopharmaceutical development services, including billings at the initiation of performance-based milestones, and recognized as revenue in the applicable future period when the revenue is earned. Also included are prepayments related to our consumer direct channel. We recognized revenue of $4.7 million and $2.9 million from deferred revenue for the years ended December 31, 2022 and 2021, respectively. The current contract liability was $4.8 million and $9.4 million as of December 31, 2022 and 2021, respectively, which was included in accrued liabilities in the consolidated balance sheets. The long-term contract liability was $0.1 million and $0.7 million as of December 31, 2022 and 2021, respectively, and was included in other long-term liabilities in the consolidated balance sheets. Refund liability As part of our strategic realignment, we terminated early or changed the scope of several companion diagnostic development contracts with milestones in progress. Upon termination, we recorded a refund liability related to the remaining outstanding performance-based milestones. The refund liability was $4.7 million and $1.2 million as of December 31, 2022 and 2021, respectively, which was included in accrued liabilities in the consolidated balance sheets. Performance obligations Test and other revenue are generally recognized upon completion of our performance obligation when or as control of the promised good or service is transferred to the customer, typically a test report or upon shipment of our precision oncology products or other contractually defined milestone(s). The Company has applied the practical expedient in relation to information about our remaining performance obligations, as we have a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date. Most remaining performance obligations are primarily related to PCM services included in test revenue in our consolidated statement of operations and are generally satisfied over one to six months.

Business combinations and dispo

Business combinations and dispositions	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business combinations and dispositions	Business combinations and dispositions Genelex and YouScript In April 2020, we acquired 100% of the equity interest of Genelex and YouScript to bring pharmacogenetic testing and integrated clinical decision support to Invitae. We acquired Genelex for approximately $13.2 million, primarily in shares of our common stock. Of the stock purchase price consideration issued, approximately 0.1 million shares were subject to a hold-back to satisfy indemnification obligations that may arise. We acquired YouScript for approximately $52.7 million, including cash consideration of $24.5 million and the remainder in shares of our common stock. Of the purchase price consideration for YouScript, approximately $1.4 million and 0.5 million shares of our common stock were subject to a hold-back to satisfy indemnification obligations that may arise. As of the acquisition date, we recorded stock payable liabilities of $6.2 million to represent the hold-back obligation to issue shares subject to indemnification claims that may arise. In April 2021, the amounts held back to satisfy indemnification obligations for Genelex were released in full to the former shareholders. As of December 31, 2021, the value of these liabilities were $3.5 million related to YouScript and were included in other long-term liabilities in the consolidated balance sheets, with the $15.4 million change in fair value year over year recorded in other income (expense), net in the consolidated statement of operations. In April 2022, the amounts held back to satisfy indemnification obligations for YouScript were released in full to the former shareholders. We may be required to pay contingent consideration in the form of additional shares of our common stock in connection with the acquisition of Genelex if, within a specified period following the closing, we achieve a certain product milestone, in which case we would issue shares of our common stock with a value equal to a portion of the gross revenues actually received by us for a pharmacogenetic product reimbursed through certain payers during an earn-out period of up to four years. As of the acquisition date, the fair value of this contingent consideration was $2.0 million. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. The material factors that may impact the fair value of the contingent consideration, and therefore, this liability, are the probabilities and timing of achieving the related milestone, the estimated revenues achieved for a pharmacogenetic product and the discount rate used to estimate the fair value. Significant changes in any of the probabilities of success would result in a significant change in the fair value, which is estimated at each reporting date. As of December 31, 2022 and 2021, the fair value of this contingent consideration was immaterial and $1.9 million, respectively. ArcherDX In October 2020, we acquired ArcherDX, a genomics analysis company. Under the terms of the agreement, we acquired ArcherDX for upfront consideration consisting of 30.0 million shares of our common stock and $325.0 million in cash, plus up to an additional 27.0 million shares of our common stock payable in connection with the achievement of certain milestones. During the three months ended March 31, 2021, Invitae and the sellers of ArcherDX reached an agreement to reduce the purchase price by $1.2 million based on the final acquired net working capital. This adjustment was recorded during the three months ended March 31, 2021 and reduced the contingent consideration liability and goodwill by approximately $1.2 million. We were required to pay contingent consideration based on achievement of post-closing development and revenue milestones. The material factors that may impact the fair value of the contingent consideration, and therefore the liability, are (i) the estimated number of shares to be issued, (ii) the volatility of our common stock, (iii) the probabilities of achievement of milestones within the timeframes prescribed in the acquisition agreement and (iv) discount rates, all of which are Level 3 inputs not supported by market activity with the exception of the volatility of our common stock. Significant changes in any of these inputs may result in a significant change in fair value, which is estimated at each reporting date. Of the five milestones, one milestone was achieved in November 2020, which resulted in the issuance of 5.0 million shares of our common stock and a cash payment of $1.9 million, and three milestones were achieved or deemed to be achieved during the three months ended June 30, 2021, which resulted in the issuance of 13.8 million shares of our common stock and a cash payment of $3.3 million in July 2021. The remaining milestone is based upon receiving FDA clearance or approval of a therapy selection IVD, which per the terms of the acquisition agreement, must be completed by March 31, 2022, subject to certain extensions (the "ArcherDX Final Milestone"). With respect to the ArcherDX Final Milestone, the liability was reduced to zero as of June 30, 2021 from $262.5 million as of March 31, 2021 and $287.7 million as of December 31, 2020, with the offsetting change recorded as changes in fair value of contingent consideration in our consolidated statements of operations. The removal of the liability balance and the associated change in fair value of contingent consideration was a result of our reassessment of the steps necessary to achieve clearance or approval based on FDA feedback received principally in the three months ended June 30, 2021. In April 2022, an agreement was entered into with the previous ArcherDX stockholders to extend the date for achievement of the ArcherDX Final Milestone to March 31, 2023. We currently do not believe that this milestone will be achieved within this timeframe. As such, no liability was recorded as of December 31, 2022. In connection with the acquisition, we granted awards of common stock to new employees who joined Invitae in connection with our acquisition of ArcherDX that vested upon the achievement of the contingent consideration milestones discussed above and were subject to the employees' continued service with us, unless terminated without cause in which case vesting was only dependent on milestone achievement. As the number of shares that were expected to be issued are fixed, the awards are equity-classified. During the year ended December 31, 2022, we recorded stock-based compensation expense of zero related to the ArcherDX milestones. During the year ended December 31, 2021, we recorded a net $41.8 million in stock-based compensation expense related to the ArcherDX milestones, which includes $38.5 million related to milestones achieved in prior periods, $33.0 million due to an accounting modification of certain awards whereby the employees' continued substantive services were no longer required, offset by a reversal of $29.7 million recognized in prior periods related to the determination that the ArcherDX Final Milestone would not be achieved within the specified timeframe prescribed in the acquisition agreement. Disposition of RUO kit assets In December 2022, we completed a transaction with IDT for net cash proceeds of $44.5 million. The transaction value includes total cash consideration of $48.1 million, subject to certain adjustments, including $3.0 million of up front consideration subject to a hold-back to satisfy indemnification obligations that may arise. The disposition is part of our strategic realignment whereby we sold to IDT select assets and liabilities related to the RUO kit product offering, which represents the RUO distributed target enrichment kit and data analysis platform of ArcherDX. The transaction also includes certain licensed rights to our AMP technology. Assets sold primarily include property and equipment and inventory with a carrying value of zero. After adjustments, the sale resulted in a gain of approximately $47.4 million during the three months ended December 31, 2022, and is included in gain on sale of RUO kit assets in our consolidated statements of operations. As of December 31, 2022, the $3.0 million of up front consideration subject to a hold-back is included within other assets in our consolidated balance sheets. Additionally, we entered into an agreement to sublease office space in Boulder, Colorado. See Note 8, "Commitments and contingencies" under the heading "Leases" for additional information regarding the sublease. One Codex In February 2021, we acquired 100% of the equity interest of One Codex, a company developing and commercializing products and services relating to microbiome sequencing, analysis and reporting, for upfront consideration consisting of $17.3 million in cash and 1.4 million shares of our common stock, of which approximately 0.2 million shares were subject to a hold-back to satisfy indemnification obligations that may have arisen following the closing. These shares subject to a hold-back were issued to a third-party at the closing date to hold in escrow until the escrow period is complete, and as such were classified as equity. In February 2022, the amounts held back to satisfy indemnification obligations were released in full to the former stockholders. Disposition of One Codex intangible assets In September 2022, we sold our equity interest in One Codex and certain related assets for an immaterial amount of cash proceeds, as part of our strategic realignment. The disposition of One Codex was considered to be an asset sale as substantially all of the fair value was concentrated in the developed technology and certain customer relationships. The carrying value of assets sold include developed technology of $19.4 million and customer relationships of $0.4 million. The sale resulted in a loss of approximately $19.8 million during the three months ended September 30, 2022, which is included in restructuring and other costs Genosity In April 2021, we acquired 100% of the fully diluted equity of Genosity, a company providing genomic laboratory services, for approximately $196.0 million, consisting of approximately $120.0 million in cash and 1.9 million shares of our common stock. In connection with this transaction, we granted RSUs having a value of up to $5.0 million to certain continuing employees and recognized $1.7 million and $0.8 million in stock-based compensation expense for the years ended December 31, 2022 and 2021, respectively. Pursuant to the terms of the acquisition, we agreed to provide additional shares in the event that our common stock share price decreased after the acquisition, but prior to filing a resale registration statement. At the time of the acquisition, we estimated this provision to be $7.0 million. On filing the resale registration statement during the period ended June 30, 2021, the fair value was $3.2 million and the difference of $3.8 million was recorded in general and administrative expense in the consolidated statements of operations. Ciitizen In September 2021, we acquired 100% of the equity of Ciitizen, a patient-centric health technology company, for approximately $308.3 million, consisting of approximately $87.4 million in cash and 6.3 million shares of our common stock, of which approximately $10.4 million in cash and 0.8 million shares are subject to a hold-back to satisfy indemnification obligations that may arise following the closing. As of December 31, 2022 and 2021, the value of the stock payable liability was $0.4 million and $12.1 million, respectively, which was recorded in other long-term liabilities in the consolidated balance sheets with the fair value change of $9.7 million and $10.6 million for the years ended December 31, 2022 and 2021, respectively, recorded as income in other income (expense), net in the consolidated statements of operations. In September 2022, the amounts held back to satisfy indemnification obligations were partially released to the former stockholders. The remaining amounts held back to satisfy indemnification obligations are expected to be released in September 2023. In connection with this transaction, we granted RSUs having a value of up to $246.9 million to certain continuing employees. During the years ended December 31, 2022 and 2021, we recorded stock-based compensation expense of $87.2 million and $24.4 million, respectively, primarily in research and development expense. Additionally, during the year ended December 31, 2022, we recorded $29.0 million of stock-based compensation expense related to the acceleration of RSUs for employees who were terminated as part of our strategic realignment, which is included in restructuring and other costs in the consolidated statements of operations. See Note 10, "Stock incentive plans" for additional information.

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in thousands): Balance as of December 31, 2021 $ 2,283,059 Impairment (2,283,059) Balance as of December 31, 2022 $ — Intangible assets The following table presents details of our acquired intangible assets as of December 31, 2022 (in thousands): December 31, 2022 Cost Accumulated Asset Disposals Net Weighted-Average Weighted-Average Customer relationships $ 41,515 $ (17,675) $ (359) $ 23,481 10.8 6.8 Developed technology 1,174,506 (183,133) (19,426) 971,947 10.8 9.3 Non-compete agreement 286 (286) — — — — Trade name 21,085 (3,964) — 17,121 12.0 9.8 Patent assets and licenses 495 (156) (339) — — — Right to develop new technology 19,359 (2,474) (16,885) — — — $ 1,257,246 $ (207,688) $ (37,009) $ 1,012,549 10.8 9.2 The following table presents details of our acquired intangible assets as of December 31, 2021 (in thousands): December 31, 2021 Cost Accumulated Net Weighted-Average Weighted-Average Customer relationships $ 41,515 $ (13,096) $ 28,419 10.8 7.8 Developed technology 662,106 (81,902) 580,204 10.2 9.1 Non-compete agreement 286 (286) — — — Trade name 21,085 (2,207) 18,878 12.0 10.8 Patent assets and licenses 495 (136) 359 15.0 10.9 Right to develop new technology 19,359 (1,613) 17,746 15.0 13.8 In-process research and development 542,388 — 542,388 n/a n/a $ 1,287,234 $ (99,240) $ 1,187,994 10.4 9.2 Acquisition-related intangibles included in the above tables are generally finite-lived, other than in-process research and development, which has an indefinite life, and are carried at cost less accumulated amortization. Customer relationships related to our 2017 business combinations are being amortized on an accelerated basis in proportion to estimated cash flows. All other finite-lived acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized. During the year ended December 31, 2022, the IVD and PCM products were fully developed resulting in the reclassification of $512.4 million of the related IPR&D intangibles to developed technology intangibles, which are finite-lived and amortizable. Amortization expense was $108.4 million, $58.8 million, and $26.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. Amortization expense is recorded in cost of revenue, research and development, and selling and marketing expense. In August 2022, in conjunction with the strategic realignment, management decided to exit the IVD product offering and we wrote-off the related intangible asset of $16.9 million. Management also decided to exit the in-vitro fertilization product offering, and as a result we wrote-off the associated intangible asset of $0.3 million. These charges are included in restructuring and other costs in the consolidated statements of operations. See Note 11, "Restructuring and other costs" for additional information. See Note 4, "Business combinations and dispositions" for additional information on the sale of our interest in One Codex and the related disposition of developed technology and customer relationships during the three months ended September 30, 2022. The following table summarizes our estimated future amortization expense of intangible assets with finite lives as of December 31, 2022 (in thousands): 2023 $ 114,440 2024 114,162 2025 112,408 2026 112,374 2027 111,708 Thereafter 447,457 Total estimated future amortization expense $ 1,012,549 In December 2021, we acquired 100% of the equity interest of Stratify, a cancer risk stratification company, for $29.0 million consisting of 1.0 million shares of common stock, $4.2 million in assumed liabilities, and $8.0 million in cash. We accounted for this transaction as an asset acquisition, as substantially all of the fair value is concentrated in the developed technology acquired. As goodwill is not recorded under an asset acquisition, an $8.7 million deferred tax liability arising from book/tax basis differences increased the value of the assets acquired above the purchase price. As a result, the fair value of the developed technology is $37.5 million, which will be amortized over eight years to cost of revenue. The remaining purchase price of $0.2 million is the fair value of cash and cash equivalents. In July 2021, we acquired 100% of the equity interest of Medneon, a digital health artificial intelligence company, for $34.1 million consisting of 0.4 million shares of common stock, $4.9 million in assumed liabilities, and $12.9 million in cash. We accounted for this transaction as an asset acquisition, as substantially all of the fair value is concentrated in the developed technology acquired. The fair value of the developed technology is $33.9 million, which will be amortized over eight years to cost of revenue. The remaining purchase price of $0.2 million is the fair value of cash and cash equivalents. Impairment assessment Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. We evaluate the fair value of long-lived assets, which include property and equipment and finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. In testing for goodwill impairment, we have the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If we elect to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, we perform a quantitative goodwill impairment test to compare to the fair value of our reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, we will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value, an adverse change in legal factors, business climate or operational performance of the business, or significant changes in the ability of a particular asset (or group of assets) to generate positive cash flows for our strategic business objectives. During the three months ended June 30, 2022, as a result of the significant, sustained decline in our stock price and related market capitalization and lower than expected financial performance, we performed an impairment assessment of goodwill, IPR&D intangible assets, and long-lived assets, including definite-lived intangibles. For our goodwill, we measured the fair value of the reporting unit utilizing the discounted cash flow method under the income approach. This approach relies on significant unobservable inputs including, but not limited to, management's forecasts of projected revenue associated with future cash flows, discount rates, and control premium. Based on this analysis, we recognized a non-cash, pre-tax goodwill impairment charge of $2.3 billion during the three months ended June 30, 2022, which was included in goodwill and IPR&D impairment expense in the consolidated statements of operations. The goodwill was fully impaired as of June 30, 2022. We also identified indicators of impairment related to the IPR&D intangible asset initially recognized as part of the acquisition of Singular Bio that it was more likely than not that the asset is impaired. The Company identified conditions during the period ended June 30, 2022 such as alternative technologies and uncertainties around the desired outcome of our in-development asset and other economic factors that raised issues with the realizability of our asset. As a result of our evaluation, we recognized a non-cash, pre-tax impairment charge of $30.0 million during the three months ended June 30, 2022 related to the IPR&D intangible asset. The impairment charges are recorded in Goodwill and IPR&D impairment expense Additionally, we recognized a loss on disposal of property and equipment of $4.8 million during the three months ended June 30, 2022 related to specific equipment that is no longer being utilized on this project and has no alternative future use. The loss on disposal is recorded in restructuring and other costs in the consolidated statements of operations. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. A recoverability test was performed for the long-lived assets, including definite-lived intangibles, using the undiscounted cash flows approach, which included significant unobservable inputs including management's forecasts of projected revenue associated with future cash flows, and residual value. The cash flow estimates reflected the Company’s assumptions about its use of the long-lived assets and eventual disposition of the asset group. We determined that our long-lived assets held and used, including intangible assets that are subject to amortization, did not have identifiable cash flows that are largely independent of the cash flows of other assets and liabilities and of other asset groups, because the assets are highly interrelated and interdependent. Therefore, the Company evaluated its long-lived assets for impairment on an entity-wide level. As a result of a recoverability test, we concluded that the carrying value of long-lived assets was recoverable at June 30, 2022. No impairment was recorded except for operating lease impairments, which are discussed under the heading "Leases" within Note 8, "Commitments and contingencies." We also recorded losses on disposal of assets pursuant to the strategic realignment, which are discussed in Note 11, "R estructuring and other costs."

Balance sheet components

Balance sheet components	12 Months Ended
	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	Balance sheet components Inventory Inventory consisted of the following (in thousands): December 31, 2022 2021 Raw materials $ 29,992 $ 27,178 Work in progress 382 5,342 Finished goods 12 996 Total inventory $ 30,386 $ 33,516 As part of the Company's strategic realignment, management decided to exit certain product offerings. During the year ended December 31, 2022, the Company wrote-off the remaining inventory related to these product offerings of $14.3 million, which is included in cost of revenue in the consolidated statements of operations. Property and equipment, net Property and equipment consisted of the following (in thousands): December 31, 2022 2021 Leasehold improvements $ 74,108 $ 31,159 Laboratory equipment 63,562 61,317 Computer equipment 13,712 15,452 Furniture and fixtures 1,428 2,130 Construction-in-progress 23,490 52,039 Other 2,996 925 Total property and equipment, gross 179,296 163,022 Accumulated depreciation and amortization (70,573) (48,308) Total property and equipment, net $ 108,723 $ 114,714 Depreciation expense was $28.8 million, $18.1 million and $10.5 million for the years ended December 31, 2022, 2021 and 2020, respectively. Depreciation expense for the year ended December 31, 2022 includes accelerated depreciation of $6.1 million from a change in the estimated useful lives of property and equipment related to the exit of certain product offerings. As part of our strategic realignment, the Company decided to exit certain business lines, consolidate lab and office space, and reduce our international footprint. During the year ended December 31, 2022, we recognized losses on disposal of property and equipment of $19.1 million, which is included in restructuring and other costs in our consolidated statement of operations. See Note 11, "Restructuring and other costs" for additional information. See Note 5, "Goodwill and intangible assets" for additional information on the impairment assessment including long-lived assets and the related loss on disposal recognized during the three months ended June 30, 2022. Accrued liabilities Accrued liabilities consisted of the following (in thousands): December 31, 2022 2021 Accrued compensation and related expenses $ 25,315 $ 35,877 Accrued expenses 23,628 32,136 Compensation and other liabilities associated with business combinations 5,335 11,622 Deferred revenue 4,814 9,431 Accrued interest 6,646 6,646 Accrued royalties 3,177 3,669 Other accrued liabilities 5,473 7,072 Total accrued liabilities $ 74,388 $ 106,453 Other long-term liabilities Other long-term liabilities consisted of the following (in thousands): December 31, 2022 2021 Compensation and other liabilities associated with business combinations, non-current $ 769 $ 27,919 Deferred revenue, non-current 50 663 Other 3,956 9,215 Total other long-term liabilities $ 4,775 $ 37,797

Fair value measurements

Fair value measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is summarized as follows: Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable. Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables set forth the fair value of our financial instruments that were measured at fair value on a recurring basis (in thousands): December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 158,931 $ — $ — $ 158,931 $ 158,931 $ — $ — U.S. Treasury notes 193,685 1 (123) 193,563 193,563 — — U.S. government agency securities 96,006 55 (13) 96,048 — 96,048 — Total financial assets $ 448,622 $ 56 $ (136) $ 448,542 $ 352,494 $ 96,048 $ — Financial liabilities: Stock payable liability $ 744 $ — $ — $ 744 Contingent consideration 25 — — 25 Total financial liabilities $ 769 $ — $ — $ 769 December 31, 2022 Reported as: Cash equivalents $ 148,901 Restricted cash 10,030 Marketable securities 289,611 Total cash equivalents, restricted cash, and marketable securities $ 448,542 Other long-term liabilities $ 769 December 31, 2021 Amortized Gross Gross Estimated Level 1 Level 2 Level 3 Financial assets: Money market funds $ 913,990 $ — $ — $ 913,990 $ 913,990 $ — $ — U.S. Treasury notes 111,187 — (6) 111,181 111,181 — — U.S. government agency securities 10,941 — (1) 10,940 — 10,940 — Total financial assets $ 1,036,118 $ — $ (7) $ 1,036,111 $ 1,025,171 $ 10,940 $ — Financial liabilities: Stock payable liability $ 20,925 $ — $ — $ 20,925 Contingent consideration 1,875 — — 1,875 Total financial liabilities $ 22,800 $ — $ — $ 22,800 December 31, 2021 Reported as: Cash equivalents $ 903,715 Restricted cash 10,275 Marketable securities 122,121 Total cash equivalents, restricted cash, and marketable securities $ 1,036,111 Other long-term liabilities $ 22,800 The following tables include a rollforward of the stock payable liability and contingent consideration classified within Level 3 of the fair value hierarchy (in thousands): Stock Payable Liability Contingent Consideration Fair value at December 31, 2021 $ 20,925 $ 1,875 Change in fair value (15,906) (1,850) Settlements (4,275) — Fair value at December 31, 2022 $ 744 $ 25 Stock Payable Liability Contingent Consideration Fair value at December 31, 2020 $ 39,237 $ 796,639 Additions 31,522 — Change in fair value (25,196) (386,646) Settlements (24,638) (408,118) Fair value at December 31, 2021 $ 20,925 $ 1,875 There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. Our debt securities of U.S. government agencies are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. At December 31, 2022, the remaining contractual maturities of available-for-sale securities ranged from one The total fair value of investments with unrealized losses at December 31, 2022 was $200.3 million. None of the available-for-sale securities held as of December 31, 2022 have been in an unrealized loss position for more than one year. The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of December 31, 2022, because the change in market value of those securities has resulted from fluctuations in market interest rates since the time of purchase, rather than a deterioration of the credit worthiness of the issuers. For marketable securities in an unrealized loss position, we assess our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. We intend to hold our marketable securities to maturity and it is unlikely that they would be sold before their cost bases are recovered. The cost of securities sold is based on the specific identification method. other income (expense)

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Leases The Company has entered into various non-cancellable operating lease agreements for office and laboratory space domestically and internationally. The Company's current leases have remaining terms ranging from approximately 1 to 12 years, some of which include options to extend the leases. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as they are not reasonably certain of being exercised. The security deposits for our operating leases are included in restricted cash in our consolidated balance sheets. In 2015, we entered into a non-cancelable operating lease agreement for our headquarters and main production facility in San Francisco, California, which commenced in 2016 with an initial lease term extending through 2026. In 2020, we entered into a non-cancelable operating lease agreement for additional office and laboratory space in San Francisco, California, which commenced in 2021 and has an initial lease term extending through 2031. In 2021, we entered into a non-cancelable operating lease agreement for a new laboratory and production facility in Morrisville, North Carolina, which commenced in the same year with an initial lease term extending through 2035. We have entered into various finance lease agreements to obtain laboratory equipment. The terms of our finance leases are generally three years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayment and related interest was classified as a finance lease obligation in our consolidated balance sheets. Finance lease assets are recorded within other assets in our consolidated balance sheets. As part of the strategic realignment, we began cost reduction initiatives including lab and office space consolidation and a reduction in our international footprint. Under this plan, we decided to cease use of certain leased premises and actively began looking to sublease certain facilities, including the related leasehold improvements. We determined that the changes in the intended use of these locations represented an indicator of impairment and performed a test of recoverability on September 30, 2022. For operating leases where the carrying values of right-of-use assets were lower than the undiscounted cash flows expected through sublease, we impaired the right-of-use assets to their fair value. The fair value was determined by utilizing the discounted cash flow method under the income approach. The key inputs to this valuation were expected sublease rental income ranging from $0.1 million to $2.8 million and discount rates ranging from 5.00% to 8.50%. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. During the three months ended September 30, 2022, we recognized an impairment charge of $4.4 million related to the right-of-use assets and $2.3 million for the related leasehold improvements, which are included in restructuring and other costs in our consolidated statements of operations. In connection with the disposition of the RUO kit assets in December 2022, we entered into an agreement to sublease a portion of our offices in Boulder, Colorado. The sublease term is concurrent with the term of the master lease extending through January 31, 2025, unless earlier terminated and with no option to extend the sublease. Per the sublease agreement, the amount of sublease payments to us will equal the amount of the master lease payments resulting in no adjustments to the right-of-use asset and related lease liability. Sublease income for the year ended December 31, 2022 was immaterial. There was no sublease income for the years ended December 31, 2021 and 2020, respectively. See Note 4, "Business combinations and dispositions" for additional information regarding the disposition of the RUO kit assets. Supplemental information regarding our operating and finance leases were as follows: Year Ended December 31, 2022 2021 Weighted-average remaining lease term: Operating leases 8.9 years 9.0 years Finance leases 1.8 years 2.4 years Weighted-average discount rate: Operating leases 6.7 % 7.0 % Finance leases 7.3 % 7.2 % Cash payments included in the measurement of lease liabilities (in millions): Operating leases $ 22.4 $ 18.3 Finance leases $ 6.2 $ 2.9 The components of lease costs, which were included in cost of revenue, research and development, and general and administrative expenses in our consolidated statements of operations, were as follows (in thousands): Year Ended December 31, 2022 2021 2020 Operating lease costs $ 24,671 $ 21,151 $ 11,329 Finance lease costs: Amortization of right-of-use assets 4,778 3,488 2,084 Interest on lease liabilities 840 496 — Total lease costs $ 30,289 $ 25,135 $ 13,413 Future payments under operating and finance leases as of December 31, 2022 are as follows (in thousands): Operating leases Finance leases 2023 $ 23,691 $ 5,595 2024 28,308 3,344 2025 17,465 495 2026 23,989 — 2027 15,863 — Thereafter 91,177 — Future non-cancelable minimum lease payments 200,493 9,434 Less: interest (51,507) (533) Total lease liabilities 148,986 8,901 Less: current portion (14,600) (5,121) Lease obligations, net of current portion $ 134,386 $ 3,780 Operating lease maturity amounts included in the table above do not include sublease income expected to be received under our sublease. Under the sublease agreement, we expect to receive sublease income for fiscal years ending December 31, 2023, 2024 and 2025 of $0.9 million, $0.9 million and $0.1 million, respectively. Debt financing In October 2020, we entered into a credit agreement with a financial institution under which we borrowed $135.0 million (the "2020 Term Loan") concurrent with the closing of the ArcherDX acquisition. The 2020 Term Loan is secured by a first priority lien on all of our and our subsidiaries' assets, and is guaranteed by us and our subsidiaries. The 2020 Term Loan bears interest at an annual rate equal to three-month LIBOR, subject to a 2.00% LIBOR floor, plus a margin of 8.75%. If three-month LIBOR can no longer be determined or if the applicable governmental authority ceases to supervise or sanction such rates, then we will endeavor to agree with the administrative agent, an alternate rate of interest that gives due consideration to the then prevailing market convention for determining interest for comparable loans in the United States, provided that until such alternative rate of interest is agreed, the 2020 Term Loan shall bear interest at the Wall Street Journal Prime Rate. The three-month LIBOR is expected to be available and representative through June 30, 2023. The 2020 Term Loan will mature on (i) June 1, 2024, if at such time our 2024 Notes (defined below) are outstanding and are due to mature on September 1, 2024 (provided that if, prior to such date, the maturity date of at least 80% of the 2024 Notes is extended to a date that is prior to September 1, 2025, the maturity date for the 2020 Term Loan will be automatically extended to a date that is 90 days prior to such 2024 Notes maturity date as extended), or (ii) otherwise, on June 1, 2025. The full amount of the 2020 Term Loan is due upon maturity. If the 2020 Term Loan is prepaid (whether such prepayment is optional or mandatory), we must pay a prepayment fee of 6% if the prepayment occurs prior to the third anniversary of the closing date or 4% if the prepayment occurs after the third anniversary of the closing date and we must also pay a make-whole fee if the prepayment occurs prior to the second anniversary of the closing date. In connection with the 2020 Term Loan, we issued warrants to purchase 1.0 million shares of our common stock with an exercise price of $16.85 per share, exercisable through October 2027. The warrants, which were classified as equity, were recorded at an amount based on the allocated proceeds and do not require subsequent remeasurement. In October 2020, these warrants were exercised in full through net settlement resulting in the issuance of 0.7 million shares. The credit agreement contains customary events of default and covenants, including among others, covenants limiting our ability to incur debt, incur liens, undergo a change in control, merge with or acquire other entities, make investments, pay dividends or other distributions to holders of our equity securities, repurchase stock, and dispose of assets, in each case subject to certain customary exceptions. In addition, the credit agreement contains financial covenants that require us to maintain a minimum cash balance and minimum quarterly revenue levels. As of December 31, 2022, the fair value of the 2020 Term Loan was $130.0 million. The estimated fair value of the 2020 Term Loan, which use Level 2 fair value inputs, was determined based on a discounted cash flow approach using the contractual term of the loan, market-based parameters such as the three-month LIBOR forward rate, and an estimate for our standalone credit risk. Debt discounts, including debt issuance costs, related to the 2020 Term Loan of $32.8 million were recorded as a direct deduction from the debt liability and are being amortized to interest expense over the term of the 2020 Term Loan. Interest expense related to our debt financings, excluding the impact of our convertible senior notes (defined below), was $24.3 million, $23.7 million and $7.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Convertible senior notes Convertible senior notes due 2024 In September 2019, we issued, at par value, $350.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "2024 Notes") in a private offering. The 2024 Notes are senior unsecured obligations and will mature on September 1, 2024, unless earlier converted, redeemed or repurchased. The 2024 Notes bear cash interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2020. Upon conversion, the 2024 Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The initial conversion rate for the 2024 Notes is 33.6293 shares of our common stock per $1,000 principal amount of the 2024 Notes (equivalent to an initial conversion price of approximately $29.74 per share of common stock). If we undergo a fundamental change (as defined in the indenture governing the 2024 Notes), the holders of the 2024 Notes may require us to repurchase all or any portion of their 2024 Notes for cash at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased plus accrued and unpaid interest to, but excluding, the redemption date. The 2024 Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding March 1, 2024, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2019 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2024 Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2024 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the 2024 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after March 1, 2024 until the close of business on the business day immediately preceding the maturity date, holders may convert their 2024 Notes at any time, regardless of the foregoing circumstances. Since issuance, these notes were convertible at the option of the holders beginning on January 1, 2021 and April 1, 2021 due to the sale price of our common stock during the quarters ended December 31, 2020 and March 31, 2021, respectively. The notes were not convertible during the year ended December 31, 2022 and there have been no significant conversions in the periods in which they were convertible. We may redeem for cash all or any portion of the 2024 Notes, at our option, on or after September 6, 2022 and on or before the 30th scheduled trading day immediately before the maturity date if the last reported sale price of the common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Convertible senior notes due 2028 In April 2021, we issued, at 99% of par value, $1,150.0 million aggregate principal amount of 1.5% convertible senior notes due 2028 (the "2028 Notes") in a private offering. The 2028 Notes are senior unsecured obligations and will mature on April 1, 2028, unless earlier converted, redeemed or repurchased. The 2028 Notes bear cash interest at a rate of 1.5% per year, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. Upon conversion, the 2028 Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The 2028 Notes will be convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by us. The 2028 Notes will be convertible into shares of our common stock based on an initial conversion rate of 23.1589 shares of common stock per $1,000 principal amount of the 2028 Notes (which is equal to an initial conversion price of $43.18 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. None of the 2028 Notes have been converted to date. We may not redeem the 2028 Notes prior to April 6, 2025. On or after April 6, 2025, the 2028 Notes will be redeemable by us in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2028 Notes, plus accrued and unpaid interest to, but excluding, the redemption date. With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges, the holders of the 2028 Notes may require that we repurchase in cash all or part of the principal amount of the Notes at a repurchase price of 100% of the principal amount of the 2028 Notes to be repurchased, plus unpaid interest to, but excluding, the maturity date. Summary of convertible senior notes We adopted the provisions of ASU 2020-06 on January 1, 2021. See Note 2, "Summary of significant accounting policies" for additional information. Our 2024 Notes and 2028 Notes (collectively, our "Convertible Senior Notes") consisted of the following (in thousands): December 31, 2022 2021 Outstanding principal $ 1,499,996 $ 1,499,996 Unamortized debt discount and issuance costs (29,213) (35,858) Net carrying amount, liability component $ 1,470,783 $ 1,464,138 As of December 31, 2022, the fair value of the 2024 Notes and 2028 Notes was $261.6 million and $576.7 million, respectively. The estimated fair value of the 2024 Notes and 2028 Notes, which use Level 2 fair value inputs, was determined based on the estimated or actual bid prices in an over-the-counter market and/or market conditions including the price and volatility of our common stock and comparable company information. We recognized $30.8 million, $24.9 million and $22.0 million of interest expense related to our Convertible Senior Notes during the years ended December 31, 2022, 2021 and 2020, respectively. Of the interest expense recognized during the years ended December 31, 2022, 2021 and 2020, $6.7 million, $5.3 million and $1.9 million, respectively, was related to amortization of issuance costs and the remainder was related to contractual interest incurred. Other commitments In the normal course of business, we enter into various purchase commitments primarily related to service agreements and laboratory supplies. At December 31, 2022, our total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands): 2023 19,756 2024 11,065 2025 1,844 2026 500 2027 250 Total $ 33,415 Guarantees and indemnification As permitted under Delaware law and in accordance with our bylaws, we indemnify our directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, we maintain director and officer liability insurance. This insurance allows the transfer of the risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record any liabilities associated with these indemnification agreements at December 31, 2022 or 2021. Contingencies We are and may from time to time be involved in various legal proceedings and claims arising in the ordinary course of business. Legal proceedings, including litigation, government investigations and enforcement actions could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if we ultimately prevail. If an investigation results in a proceeding against us, an adverse outcome could include us being required to pay treble damages, and incur attorneys’ fees, civil or criminal penalties and other adverse actions that could materially and adversely affect our business, financial condition and results of operations. While we believe any such claims are unsubstantiated, and we believe we are in compliance with applicable laws and regulations applicable to our business, the resolution of any such claims could be material. We were not a party to any material legal proceedings at December 31, 2022, or at the date of this report except for matters listed below. We cannot currently predict the outcome of these actions. Natera, Inc. On January 27, 2020, Natera filed a lawsuit against ArcherDX (a subsidiary of Invitae effective October 2, 2020) in the United States District Court for the District of Delaware, alleging that ArcherDX’s products using AMP chemistry, and the manufacture, use, sale, and offer for sale of such products, infringe U.S. Patent No. 10,538,814. On March 25, 2020, ArcherDX filed an answer denying Natera’s allegations and asserting certain affirmative defenses and counterclaims, including that U.S. Patent No. 10,538,814 is invalid and not infringed. On April 15, 2020, Natera filed an answer denying ArcherDX’s counterclaims and filed an amended complaint alleging that ArcherDX’s products using AMP chemistry, including STRATAFIDE, PCM, LiquidPlex, ArcherMET, FusionPlex, and VariantPlex, and the manufacture, use, sale, and offer for sale of such products, infringe U.S. Patent No. 10,538,814, U.S. Patent No. 10,557,172, U.S. Patent No. 10,590,482, and U.S. Patent No. 10,597,708, each of which are held by Natera. Natera seeks, among other things, damages and other monetary relief, costs and attorneys’ fees, and an order enjoining ArcherDX from further infringement of such patents. On May 13, 2020, ArcherDX filed an answer to Natera’s amended complaint denying Natera’s allegations and asserting certain affirmative defenses and counterclaims, including that the asserted patents are invalid and not infringed. On June 3, 2020, Natera filed an answer denying ArcherDX’s counterclaims. On June 4, 2020, ArcherDX filed a motion seeking dismissal of Natera’s infringement claims against STRATAFIDE, PCM, and ArcherMET, and for a judgment that U.S. Patent No. 10,538,814, U.S. Patent No. 10,557,172, and U.S. Patent No. 10,590,482 are invalid. On August 6, 2020, Natera filed another complaint against ArcherDX in the United States District Court for the District of Delaware alleging that ArcherDX’s products using AMP chemistry, including STRATAFIDE, PCM, LiquidPlex, ArcherMET, and VariantPlex, and the manufacture, use, sale, and offer for sale of such products, infringe U.S. Patent No. 10,731,220. Natera seeks, among other things, damages and other monetary relief, costs and attorneys’ fees, and an order enjoining ArcherDX from further infringement of the patent. On October 13, 2020, the court issued an order denying ArcherDX's motion for dismissal of Natera’s infringement claims against STRATAFIDE, PCM, and ArcherMET, and declined to enter judgment that U.S. Patent No. 10,538,814, U.S. Patent No. 10,557,172, and U.S. Patent No. 10,590,482 are invalid. On January 12, 2021, the court issued an order granting Natera leave to amend its complaint to add Invitae as a co-defendant and plead allegations that ArcherDX and Invitae induce end-users to infringe the patents-in-suit. Natera filed its second amended complaint ("Second Amended Complaint") on the same day, with service completed on January 15, 2021. ArcherDX and Invitae filed answers to the Second Amended Complaint on January 26, 2021 and February 5, 2021, respectively, denying Natera's allegations and restating certain affirmative defenses and counterclaims of non-infringement and invalidity. The litigations have now been consolidated for all purposes. A claim construction order was issued on June 28, 2021. On October 27, 2021, Natera filed its third amended complaint ("Third Amended Complaint") to add a Certificate of Correction to U.S. Patent No. 10,590,482. On November 3, 2021, ArcherDX filed its answer and counterclaims to Natera's Third Amended Complaint, adding an inequitable conduct defense and declaratory judgment counterclaims. Discovery concluded in December 2021. On January 21, 2022, Natera, ArcherDX and Invitae moved for summary judgment, wherein Natera seeks a determination on certain legal and equitable defenses and ArcherDX and Invitae seek a determination of non-infringement and invalidity of the asserted patents. The court denied the parties' respective summary judgment motions by order dated February 6, 2023. Trial is set for May 8, 2023. In addition, on October 6, 2020, Natera filed a complaint against Genosity in the United States District Court for the District of Delaware, alleging that Genosity's use of its AsTra products, and the manufacture, use, sale, and offer for sale of such products, infringes U.S. Patent No. 10,731,220. Natera's complaint further alleges that Genosity's accused products use ArcherDX's ctDNA and region-specific primers. Genosity filed an answer to the complaint on February 15, 2021, denying Natera's allegations and setting forth affirmative defenses and counterclaims of non-infringement, invalidity and unenforceability due to inequitable conduct. On March 8, 2021, Natera filed a motion to dismiss and strike certain affirmative defenses and counterclaims brought by Genosity relating to inequitable conduct. The court denied that motion on March 14, 2022. The court granted an order granting the parties' stipulated request to stay the case on April 1, 2022. QIAGEN Sciences On July 10, 2018, ArcherDX and the General Hospital Corporation d/b/a Massachusetts General Hospital, which we refer to as MGH, filed a lawsuit in the United States District Court for the District of Delaware against QIAGEN Sciences, LLC, QIAGEN LLC, QIAGEN Beverly, Inc., QIAGEN Gaithersburg, Inc., QIAGEN GmbH and QIAGEN N.V., which is collectively referred to herein as QIAGEN, and a named QIAGEN executive who was a former

Stockholders' equity

Stockholders' equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ equity	Stockholders’ equity Shares outstanding Shares of convertible preferred and common stock were as follows (in thousands): Year Ended December 31, 2022 2021 2020 Convertible preferred stock: Shares outstanding, beginning of period — 125 125 Conversion into common stock — (125) — Shares outstanding, end of period — — 125 Common stock: Shares outstanding, beginning of period 228,116 185,886 98,796 Common stock issued in private placement — — 16,320 Common stock issued in connection with public offering 2,429 8,932 24,005 Common stock issued on exercise of stock options, net 159 2,068 2,659 Common stock issued pursuant to vesting of RSUs 10,486 4,325 5,304 Common stock issued pursuant to exercises of warrants — 208 968 Common stock issued pursuant to employee stock purchase plan 2,231 654 671 Common stock issued pursuant to acquisitions 2,141 25,918 37,163 Common stock issued upon conversion of preferred stock — 125 — Shares outstanding, end of period 245,562 228,116 185,886 Common Stock As of December 31, 2022, we had 600 million shares of common stock authorized with a par value of $0.0001. The number of authorized shares increased from 400 million to 600 million during the year ended December 31, 2022. Convertible preferred stock In August 2017, in a private placement to certain accredited investors, we issued shares of our Series A convertible preferred stock which are convertible into common stock on a one-for-one basis, subject to adjustment for events such as stock splits, combinations and the like. The Series A convertible preferred stock is a non-voting common stock equivalent with a par value of $0.0001 and has the right to receive dividends first or simultaneously with payment of dividends on common stock. In the event of any liquidation or dissolution of the Company, the Series A preferred stock is entitled to receive $0.001 per share prior to the payment of any amount to any holders of capital stock ranking junior to the Series A preferred stock and thereafter shall participate pari passu with the holders of our common stock (on an as-if-converted-to-common-stock basis). During the year ended December 31, 2021, 124,913 shares of Series A convertible preferred stock were converted into 124,913 shares of common stock. As of December 31, 2022 and 2021, we had 20 million shares of preferred stock authorized, of which 3,458,823 shares were designated as Series A convertible preferred stock. As of December 31, 2022 and 2021, there were no shares of preferred stock or Series A convertible preferred stock outstanding. Sales Agreements In May 2021, we entered into a sales agreement (the "2021 Sales Agreement") with Cowen and Company, LLC (“Cowen”) under which we may offer and sell from time to time at our sole discretion shares of our common stock through Cowen as our sales agent, in an aggregate amount not to exceed $400.0 million. Per the terms of the agreement, Cowen will receive a commission of up to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2021 Sales Agreement. During the year ended December 31, 2022, we sold a total of 2.4 million shares of common stock under the 2021 Sales Agreement at an average price of $3.99 per share, for gross proceeds of $10.0 million and net proceeds of $9.7 million. During the year ended December 31, 2020, we sold a total of 3.6 million shares of common stock under the common stock sales agreement entered into with Cowen in August 2018 at an average price of $26.33 per share, for gross proceeds of $93.7 million and net proceeds of $90.7 million. Public offerings In January 2021, we sold, in an underwritten public offering, an aggregate of 8.9 million shares of our common stock at a price of $51.50 per share, for gross proceeds of $460.0 million and net proceeds of approximately $434.3 million after deducting underwriting discounts and commissions and offering expenses. In April 2020, we sold, in an underwritten public offering, an aggregate of 20.4 million shares of our common stock at a price of $9.00 per share, for gross proceeds of $184.0 million and net proceeds of $173.0 million after deducting underwriting discounts and commissions and offering expenses. Private placement

Stock incentive plans

Stock incentive plans	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock incentive plans	Stock incentive plans Stock incentive plans In 2010, we adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by our board of directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than the fair market value of our common stock. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market value of our common stock on the grant date, as determined by our board of directors. The terms of options granted under the 2010 Plan may not exceed ten years. In January 2015, we adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of our initial public offering. Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards. Options granted generally vest over a period of four years. Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule. Upon the acquisition of ArcherDX in October 2020, any option that was outstanding was converted into a fully vested option to purchase a share of our common stock, which resulted in the issuance of options to purchase 3.7 million shares of our common stock. RSUs generally vest ratably in annual installments over a period of three years, commencing on the first anniversary of the grant date, with certain awards that include a portion that vests immediately upon grant. The vesting schedule for the 2022 grants approved in April 2022 provides that the awards vest ratably in quarterly installments over a period of two years, with certain awards that include a portion that vests immediately upon grant. Grants to the executive team in 2022 vest ratably in annual installments over a period of three years. We have also granted certain awards in connection with our management incentive plan that vest over a period of two years. In June 2019, we granted time-based RSUs in connection with an acquisition and PRSUs that vested based on the achievement of performance conditions, both of which were fully vested as of December 31, 2022. In December 2020, we granted RSUs in connection with an asset acquisition which were fully vested as of December 31, 2022. Under our management incentive compensation plan, in July 2019 we granted PRSUs to our executive officers as well as other specified senior level employees based on the level of achievement of a specified 2019 revenue goal. One-third of the 0.8 million shares that were ultimately awarded under this plan vested during the year ended December 31, 2020 and the remaining shares vested through March 2022. In June 2020, we granted 0.3 million PRSUs under this plan which are based on the level of achievement of a specified 2020 cash burn goal. Upon achievement of the specified 2020 cash burn goal, 0.3 million shares were ultimately awarded and vested in 2021 over a one Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share data and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Balances at December 31, 2021 10,242 3,034 $ 11.98 5.5 $ 16,431 Additional shares reserved 9,125 — Options granted (1,121) 1,121 $ 3.03 Options cancelled 1,455 (1,455) $ 12.04 Options exercised — (159) $ 4.06 RSUs and PRSUs granted (12,508) — RSUs and PRSUs cancelled 5,432 — Balances at December 31, 2022 12,625 2,541 $ 8.49 6.6 $ 16 Options exercisable at December 31, 2022 1,384 $ 11.21 4.1 $ 16 Options vested and expected to vest at December 31, 2022 2,383 $ 8.84 6.1 $ 16 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of our common stock for stock options that were in-the-money. The weighted-average fair value of options to purchase common stock granted was $2.07, $22.46 and $10.10 in the years ended December 31, 2022, 2021 and 2020, respectively. The total grant-date fair value of options to purchase common stock vested was $1.8 million, $2.4 million and $2.8 million in the year ended December 31, 2022, 2021, and 2020, respectively. The intrinsic value of options to purchase common stock exercised was $0.7 million, $55.0 million and $104.4 million in the years ended December 31, 2022, 2021 and 2020, respectively. The following table summarizes RSU, including PRSU, activity (in thousands, except per share data): Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at December 31, 2021 16,247 $ 26.21 RSUs granted 11,622 $ 5.58 Time-based RSUs and PRSUs granted - variable 886 $ 2.47 RSUs vested (11,428) $ 23.03 RSUs cancelled (5,432) $ 16.67 Balance at December 31, 2022 11,895 $ 11.70 2015 ESPP In January 2015, we adopted the 2015 ESPP, which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At December 31, 2022, cash received from payroll deductions pursuant to the ESPP was $1.3 million. The ESPP provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 and continuing through January 1, 2025. At December 31, 2022, a total of 2.1 million shares of common stock are reserved for issuance under the ESPP. Stock-based compensation We use the grant date fair value of our common stock to value options when granted. In determining the fair value of stock options and ESPP purchases, we use the Black-Scholes option-pricing model and, for stock options, the assumptions discussed below. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of RSU and PRSU awards is based on the grant date share price. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options and RSUs and on an accelerated basis for PRSUs. Fair value of common stock —The fair value of each share of common stock is based on the closing price of our common stock on the date of grant as reported on the NYSE. Expected term —The expected term represents the period that our stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). Expected volatility —We estimate expected volatility based on the historical volatility of our common stock over a period equal to the expected term of stock option grants and RSUs and over the expected six-month term ESPP purchase periods. Risk-free interest rate —The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. Dividend yield —We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero. The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions: Year Ended December 31, 2022 2021 2020 Fair value of common stock $2.85 - $5.22 $34.90 $16.17 - $16.55 Expected term (in years) 6.0 6.0 6.0 Expected volatility 77.6% 73.5% 71.0% Risk-free interest rate 3.0% 1.1% 0.5% The fair value of shares purchased pursuant to the ESPP is estimated using the Black-Scholes option pricing model. For the years ended December 31, 2022, 2021 and 2020, the weighted-average grant date fair value per share for the ESPP was $2.34, $8.10 and $10.98, respectively. The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions: Year Ended December 31, 2022 2021 2020 Expected term (in years) 0.5 0.5 0.5 Expected volatility 200.6% 66.1% 105.7% Risk-free interest rate 3.6% 0.0% 0.1% The following table summarizes stock-based compensation expense for the years ended December 31, 2022, 2021 and 2020, included in the consolidated statements of operations (in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenue $ 6,868 $ 12,033 $ 8,713 Research and development 113,843 92,407 91,762 Selling and marketing 12,897 15,641 14,418 General and administrative 35,378 59,994 43,854 Restructuring and other costs 30,318 — — Total stock-based compensation expense $ 199,304 $ 180,075 $ 158,747 Stock-based compensation expense included in restructuring and other costs was related to the accelerated vesting of RSUs held by certain employees whose employment was terminated as part of the strategic realignment. Pursuant to the terms and conditions of the Ciitizen transaction, employees were deemed vested in any unvested RSUs at the time of their termination. See Note 11, "Restructuring and other costs" for additional information. At December 31, 2022, unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, was $3.4 million, which we expect to recognize on a straight-line basis over a weighted-average period of 3.3 years. Unrecognized compensation expense related to RSUs, including PRSUs, and awards that are contingently issuable upon the completion of certain milestones related to our acquisitions of ArcherDX and IntelliGene Health Informatics, LLC at December 31, 2022, net of estimated forfeitures, was $154.0 million, which we expect to recognize on a straight-line basis over a weighted-average period of 1.5 years.

Restructuring and other costs

Restructuring and other costs	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring and other costs	Restructuring and other costs On July 18, 2022, we initiated a strategic realignment of our operations to reduce operating costs and drive future growth aligned with our core genetic testing and data platform and patient network. The strategic realignment includes a reduction in workforce, lab and office space consolidation, portfolio optimization, decrease in other operating expenses, as well as a reduced international footprint. Under this strategic realignment, we reduced our workforce by approximately 1,000 employees with a majority of these employees separating from the Company by September 30, 2022 and the remaining affected employees transitioning over varying periods of time up to 12 months. Employees who were impacted by the restructuring were eligible to receive severance benefits contingent upon an impacted employee’s execution (and non-revocation, where applicable) of a separation agreement, which included a general release of claims against us. The following table summarizes the expenses related to our strategic realignment recognized in restructuring and other costs in our consolidated statement of operations (in thousands): Year Ended December 31, 2022 Employee severance and benefits $ 65,556 Impairments and losses on disposals of long-lived assets 60,507 Other restructuring costs 14,268 Total restructuring and other costs $ 140,331 Employee severance and benefits are comprised of severance, other termination benefit costs, and stock-based compensation expense for the acceleration of RSUs related to workforce reductions. See Note 10, "Stock incentive plans" for additional information about the accelerated vesting of RSUs. Asset impairments and losses on asset disposals include operating lease impairments, losses on disposals of property and equipment and leasehold improvements associated with exiting lines of business, consolidating lab and office space, and reducing our international footprint. See Note 8, "Commitments and contingencies" under the heading "Leases" for additional information about operating lease impairments. See Note 5, "Goodwill and intangible assets" for additional information about the loss on disposal of property and equipment related to the Singular Bio acquisition and Note 6, "Balance sheet components" for additional information about losses on disposal of property and equipment. Other restructuring costs include the write-off of prepaid assets related to the exit of certain product offerings, legal and professional fees, and contract exit costs. We expect to incur additional employee severance and benefits expenses up to $1.2 million, and additional other restructuring costs primarily related to third-party costs up to $3.5 million. This reflects the best estimate of the Company, which may be revised in subsequent periods as the strategic realignment progresses. The following table summarizes the changes in liabilities associated with our strategic realignment initiatives, including restructuring and other costs incurred and cash payments as of December 31, 2022 (in thousands): Employee severance and benefits Other restructuring costs Total Beginning balance $ — $ — $ — Accruals 35,237 7,405 42,642 Payments (32,974) (5,464) (38,438) Balance at December 31, 2022 $ 2,263 $ 1,941 $ 4,204 The restructuring liabilities are included in accrued liabilities in the consolidated balance sheets. We expect that substantially all of the remaining accrued restructuring liabilities will be paid in cash over the next 12 months. The charges recognized in the roll forward of our accrued restructuring liabilities do not include items charged directly to expense for losses on asset disposals, accelerated vesting of RSUs, and other periodic exit costs, as those items are not reflected in our restructuring liabilities in our consolidated balance sheets.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income taxes We recorded a benefit for income taxes in the years ended December 31, 2022, 2021 and 2020. The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands): Year Ended December 31, 2022 2021 2020 United States $ 3,147,669 $ 414,657 $ 712,409 Foreign 3,528 1,206 1,861 Total $ 3,151,197 $ 415,863 $ 714,270 The components of the provision for income taxes are as follows (in thousands): Year Ended December 31, 2022 2021 2020 Current: Foreign 1,338 (2,069) (171) Total current benefit (expense) for income taxes 1,338 (2,069) (171) Deferred: Federal 22,368 28,348 94,279 State 19,512 8,809 17,730 Foreign 1,686 1,769 262 Total deferred benefit for income taxes 43,566 38,926 112,271 Total income tax benefit $ 44,904 $ 36,857 $ 112,100 The following table presents a reconciliation of the tax expense computed at the statutory federal rate and our tax expense for the periods presented: Year Ended December 31, 2022 2021 2020 U.S. federal taxes at statutory rate 21.0 % 21.0 % 21.0 % State taxes (net of federal benefit) 0.9 % 7.3 % 3.4 % Stock-based compensation (1.2) % (1.2) % (1.6) % Research and development credits 0.4 % 3.8 % 1.1 % Non-deductible expenses — % (0.9) % (0.7) % Foreign tax differential 0.1 % (0.1) % — % Acquisition contingent liabilities 0.1 % 18.5 % (0.8) % Non-deductible impairment expense (14.9) % — % — % Change in valuation allowance (4.9) % (39.5) % (6.7) % Total 1.5 % 8.9 % 15.7 % The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 595,301 $ 530,663 Tax credits 49,615 36,188 R&D capitalization and amortization 72,358 6,202 Revenue recognition differences — 2,560 Leasing liabilities 36,986 34,403 Accruals and other 41,198 36,689 Gross deferred tax assets 795,458 646,705 Valuation allowance (542,900) (386,950) Total deferred tax assets 252,558 259,755 Deferred tax liabilities: Amortization and depreciation (216,899) (277,719) Revenue recognition differences (14,180) — Leasing assets (29,609) (33,732) Total deferred tax liabilities (260,688) (311,451) Net deferred tax liabilities $ (8,130) $ (51,696) The Company historically established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. In 2022 the Company released approximately $41.9 million of its valuation allowance, primarily due to the release of federal and state valuation allowances as a result of the reclassification of ArcherDX's IVD and PCM in-process research and development intangibles from indefinite-lived intangibles to developed technology, which enabled the associated deferred tax liability to serve as a source of income to existing finite-lived deferred tax assets for which a valuation allowance had previously been established. Effective for tax years beginning on or after January 1, 2022, pursuant to the Tax Cuts and Jobs Act of 2017, companies are required to capitalize and amortize Internal Revenue Code Section 174 research and experimental expenses paid or incurred over five years for research and development performed in the United States and 15 years for research and development performed outside of the United States. As a result of the Internal Revenue Code Section 174 research and experimental expense capitalization, the Company recognized a deferred tax asset for the future tax benefit of the amortization deductions with offsetting increase in the valuation allowance on deferred tax assets. Due to the overall increase of deferred tax assets, the Company's valuation allowance also increased from the prior year. The Company's valuation allowance increased by $155.9 million, $177.6 million, and $64.0 million during the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, the Company had net operating loss carryforwards of approximately $2.4 billion and $1.5 billion available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. Of the $2.4 billion, $285.0 million will begin to expire in 2030 while $2.1 billion have no expiration date. The state net operating loss carryforwards will begin to expire in 2030. As of December 31, 2022, the Company had research and development credit carryforwards of approximately $79.9 million and $32.2 million available to reduce our future tax liability, if any, for federal and state income tax purposes, respectively. The federal credit carryforwards begin to expire in 2030. California credit carryforwards have no expiration date. Internal Revenue Code ("IRC") section 382 places a limitation (the “Section 382 limitation” or “annual limitation”) on the amount of taxable income that can be offset by net operating loss carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Similar provisions exist for states. In addition, and as a result of the acquisitions of Good Start Genetics and CombiMatrix in 2017, acquisitions of Singular Bio, Jungla, and Clear Genetics in 2019, acquisitions of YouScript and ArcherDX in 2020, and acquisitions of One Codex, Genosity, Ciitizen, and Stratify in 2021, tax loss carryforwards from acquired entities are also subject to the Section 382 limitation due to the change in control in the acquired entities in the current year. In addition, the Company also performed a section 382 analysis in 2022 with respect to our operating loss and credit carryforwards. The Company concluded while an ownership change occurred in 2020 as defined under IRC section 382, none of the Company's net operating loss carryforwards would expire unused solely as a result of annual limitations imposed on the use of the carryforwards under IRC sections 382 and 383. Our policy with respect to undistributed foreign subsidiaries’ earnings is to consider those earnings to be indefinitely reinvested. As a result of the enactment in the Tax Cuts and Job Acts of 2017, if and when funds are actually distributed in the form of dividends or otherwise, we expect minimal tax consequences, except for withholding taxes, which would be applicable in some jurisdiction. As of December 31, 2022, we had unrecognized tax benefits of $59.3 million, which primarily relates to research and development credits, $0.2 million of which would currently affect the Company's effective tax rate if recognized due to the Company's valuation allowance against its deferred tax assets. During the year, the Company benchmarked the reserves of similar tax positions within the industry based on IRS and state audits of comparable companies. Based on its analysis, the Company decreased its unrecognized tax benefits to more closely align with other comparable companies within the industry. As these reserves relate primarily to research and development credits which have a full valuation allowance, such adjustments did not impact the Company's income tax provision. Unrecognized tax benefits are not expected to materially change in the next 12 months. On November 3, 2022, the Dutch tax authorities published a decree on the Anti-Tax Avoidance Directive 2 (“ATAD2”) that relieves the Company of the application of ATAD2 in Netherlands. As a result, the Company has released $1.7 million of related reserve for the uncertain tax position. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year ended December 31, 2022 2021 2020 Unrecognized tax benefits, beginning of period $ 46,669 $ 21,965 $ 26,985 Gross increases—current period tax positions 14,161 18,165 8,368 Gross increases—prior period tax positions 243 6,539 53 Gross decreases—prior period tax positions (1,739) — (13,441) Unrecognized tax benefits, end of period $ 59,334 $ 46,669 $ 21,965 The Company's policy is to include penalties and interest expense related to income taxes as a component of tax expense. The Company has not accrued interest and penalties related to the unrecognized tax benefits reflected in the financial statements for the years ended December 31, 2022, 2021 and 2020. The Company's major tax jurisdictions are the United States and California. All of the Company's tax years will remain open for examination by the Federal and state tax authorities for three

Net loss per share

Net loss per share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net loss per share	Net loss per share The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data): Year ended December 31, 2022 2021 2020 Net loss $ (3,106,293) $ (379,006) $ (602,170) Shares used in computing net loss per share, basic and diluted 235,676 210,946 134,587 Net loss per share, basic and diluted $ (13.18) $ (1.80) $ (4.47) The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Year Ended December 31, 2022 2021 2020 Shares of common stock subject to outstanding options 3,113 4,069 6,878 Shares of common stock subject to outstanding warrants — 29 405 Shares of common stock subject to outstanding RSUs 17,874 9,146 5,590 Shares of common stock subject to outstanding PRSUs 148 737 1,658 Shares of common stock pursuant to ESPP 1,891 425 294 Shares of common stock underlying Series A convertible preferred stock — 93 125 Shares of common stock subject to Convertible Senior Notes conversion 38,403 38,403 8,371 Total shares of common stock equivalents 61,429 52,902 23,321

Geographic information

Geographic information	12 Months Ended
	Dec. 31, 2022
Segments, Geographical Areas [Abstract]
Geographic information	Geographic information Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands): Year Ended December 31, 2022 2021 2020 United States $ 457,061 $ 404,013 $ 255,680 United Kingdom 9,185 5,485 2,185 Canada 8,779 7,553 4,529 Germany 5,445 8,102 2,299 Rest of world 35,833 35,296 14,905 Total revenue $ 516,303 $ 460,449 $ 279,598 As of December 31, 2022, 2021 and 2020, our long-lived assets were primarily located in the United States other than operating lease assets representing our right-of-use for leased facilities in Australia, Belgium and Israel.

Selected quarterly data (unaudi

Selected quarterly data (unaudited)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly data (unaudited)	Selected quarterly data (unaudited) The following tables summarize our quarterly financial information for 2022 and 2021 (in thousands, except per share amounts): Three Months Ended March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 Revenue $ 123,691 $ 136,622 $ 133,536 $ 122,454 Cost of revenue $ 97,116 $ 110,340 $ 116,956 $ 92,844 Loss from operations $ (213,233) $ (2,520,331) $ (289,951) $ (94,895) Net loss $ (181,859) $ (2,523,461) $ (301,156) $ (99,817) Net loss per share, basic and diluted (1) $ (0.80) $ (10.87) $ (1.27) $ (0.41) Three Months Ended March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 Revenue $ 103,621 $ 116,312 $ 114,395 $ 126,121 Cost of revenue $ 75,491 $ 89,331 $ 87,741 $ 96,106 (Loss) income from operations $ (112,364) $ 128,609 $ (193,312) $ (214,574) Net (loss) income $ (109,492) $ 133,786 $ (198,176) $ (205,124) Net (loss) income per share, basic (1) $ (0.56) $ 0.66 $ (0.91) $ (0.90) Net (loss) income per share, diluted (1) $ (0.56) $ 0.53 $ (0.91) $ (0.90) ___________________________________________________________________ (1) Net (loss) income per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net (loss) income per share information may not equal annual net (loss) income per share.

Subsequent event

Subsequent event	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent event	Subsequent events Payments made on 2020 Term Loan On February 7, 2023, the Company made a $53.7 million payment which reduced the principal balance of the 2020 Term Loan by $50.0 million and included a $3.0 million prepayment fee, with the remainder attributable to interest. The payment was made by the Company at its sole election. On February 28, 2023, the Company repaid the remaining principal balance outstanding of $85.0 million plus outstanding interest of $1.9 million and a prepayment fee of $5.1 million. Debt transactions On February 28, 2023, the Company announced it has entered into agreements with certain holders of the currently outstanding 2024 Notes. Under the terms of the agreement, Company will (a) exchange approximately $305.7 million aggregate principal amount of the 2024 Notes for approximately $275.3 million aggregate principal amount of its new 4.50% Series A Convertible Senior Secured Notes due 2028 (“New 2028 Notes”) and $30.6 million of the Company’s common stock and (b) issue and sell $30.0 million of New 2028 Notes for cash (collectively, the “Transactions”). The Transactions are subject to customary closing conditions and are expected to close on or about March 7, 2023. The New 2028 Notes will be issued pursuant to an indenture. Under the terms of the agreement, the Company will have the option prior to the maturity date to redeem all or any portion of the principal amount of the New 2028 Notes for cash and warrants to purchase common stock at a ratio as outlined in the indenture. The New 2028 Notes will be convertible at any time prior to the maturity date at the option of the holders, subject to a beneficial ownership cap. In addition, prior to such time that the Company obtains stockholder approval for the issuance of shares of common stock in excess of the limitations imposed by the NYSE rules (the “NYSE Cap”), the holder is prohibited from converting New 2028 Notes into shares of common stock in excess of such NYSE Cap and the Company would instead be required to settle any conversion in cash if the Company is not able to obtain the stockholder approval within the grace period specified in the indenture. The New 2028 Notes will be secured by (i) a security interest in substantially all of the assets of the Company and its material subsidiaries and (ii) a pledge of the equity interests of the Company’s direct and indirect material subsidiaries. The indenture includes specific affirmative and restrictive covenants agreed to by the Company.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation Our consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis. Significant estimates and assumptions made by management include the determination of: • revenue recognition; • inventory adjustments; • the fair value of assets and liabilities associated with business combinations; • the impairment assessment of goodwill and intangible assets; • the recoverability of long-lived assets; • our incremental borrowing rates used to calculate our lease balances; • stock-based compensation expense and the fair value of awards and warrants issued; and • income tax uncertainties.
Concentrations of credit risk and other risks and uncertainties	Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, restricted cash, marketable securities and accounts receivable. Our cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.
Cash, cash equivalents, and restricted cash	Cash, cash equivalents, and restricted cash We consider all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds, U.S. Treasury notes and government agency securities. Restricted cash consists primarily of money market funds that secure irrevocable standby letters of credit that serve as collateral for security deposits for our facility leases.
Marketable securities	Marketable securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. Short-term marketable securities have maturities one year or less at the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive loss. Realized gains and losses and impairments, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in other income (expense), net. For marketable securities in an unrealized loss position, we assess our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the security’s amortized cost basis is written down to fair value through other income (expense), net.
Accounts receivable	Accounts receivableWe receive payment from patients, biopharmaceutical partners, third-party payers and other business-to-business customers.
Allowance for losses on certain financial assets	Allowances for losses on certain financial assets We assess our accounts receivables for expected credit losses at each reporting period by disaggregating by payer type and further by portfolios of customers with similar characteristics, such as customer type and geographic location. We then review each portfolio for expected credit losses based on historical payment trends as well as forward looking data and current economic trends. If a credit loss is determined, we record a reduction to our accounts receivable balance with a corresponding general and administrative expense. We review available-for-sale debt securities in an unrealized loss positions at each balance sheet date and assess whether such unrealized loss positions are credit-related. Our expected loss allowance methodology for these securities is developed by reviewing the extent of the unrealized loss, the issuers’ credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers’ current status and financial condition. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income (expense), net. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss.
Deferred revenue	Deferred revenueWe record a contract liability when cash payments are received or due in advance of our performance related to one or more performance obligations. Revenue recognition We recognize revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. We utilize the following practical expedients and exemptions: • Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year or less, and • No adjustments to promised consideration were made for financing as we expect, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less. Test revenue Test revenue is comprised of testing services and sales of distributed precision oncology products. The majority of our test revenue is generated from genetic testing, in addition to somatic testing for therapy selection and personalized cancer monitoring. These testing services provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions or contractual agreements, and we often enter into contracts with insurance companies and institution customers that include pricing provisions under which such tests are billed. Billing terms are generally net 30 to 60 days. While the transaction price of diagnostic tests is originally established either via contract or pursuant to our standard list price, we often provide concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which we will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed each reporting period and updated as necessary. We look to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with the service portion of our diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on our web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a 30-day period. We also generated test revenue through the sale of our distributed precision oncology products, which is comprised primarily of sales of our RUO kit and IVD product offerings for therapy selection. We recognized revenue on these sales once shipment had occurred. Product sales were recorded net of discounts and other deductions. Billing terms were generally net 30 days. As part of the strategic realignment, we exited these product offerings in fiscal year 2022. See Note 4, "Business combinations and dispositions" for additional information on the disposition of the RUO kit assets. See Note 5, "Goodwill and intangible assets" for additional information on the exit of the IVD product offering. Shipping and handling fees billed to customers are recorded as revenue in the consolidated statements of operations. The associated shipping and handling costs are recorded as cost of revenue. Other revenue Other revenue is primarily generated from collaboration agreements and genome network contracts as well as pharma development services provided to biopharmaceutical companies related to companion diagnostic development. We enter into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the data and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods. Amounts due under collaboration and genome network agreements are typically billable on net 30-day terms. Contracts for companion diagnostic development consisted primarily of milestone-based payments along with annual fees and marked-up pass-through costs. The arrangements were treated as short-term contracts for revenue recognition purposes because they allow termination of the agreements by the customers with 30 to 120 days’ written notice without a termination penalty. Upon termination, customers were required to pay for the proportion of services provided under milestones that were in progress. We recognized revenue in an amount that reflected the consideration which we expect to receive in exchange for those goods or services. We recognized revenue as services are provided based on the progress made toward achieving the performance obligation, utilizing input methods, including labor hours expended and tests processed, that measure our progress toward the achievement of the milestone. Cost of revenue Cost of revenue reflects the aggregate costs incurred in delivering our products and services and includes expenses for materials and supplies, personnel-related costs, freight, costs for lab services and clinical trial support, equipment and infrastructure expenses and allocated overhead including rent, information technology costs, equipment depreciation, amortization of acquired intangibles, and utilities.
Inventory	Inventory Our inventory consists of raw materials, work in progress, and finished goods, which are stated at the lower of cost or net realizable value on a first-in, first-out basis. We periodically analyze our inventory levels and expiration dates, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its net realizable value, and inventory in excess of expected sales requirements as cost of revenue. We record an allowance for obsolete inventory using an estimate based on historical trends and evaluation of near-term expirations.
Business combinations and asset acquisitions	Business combinations We apply ASC 805, Business Combinations , which requires recognition of assets acquired, liabilities assumed, and contingent consideration at their fair value on the acquisition date with subsequent changes recognized in earnings; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination and expensed as incurred; requires in-process research and development to be capitalized at fair value as an indefinite-lived intangible asset until completion or abandonment; and requires that changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period be recognized as a component of provision for taxes. We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. We base the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by our management, which consider our estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity , we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We remeasure this liability each reporting period and record changes in the fair value in change in fair value of contingent consideration in our consolidated statements of operations. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in our operating results from the date of acquisition. Asset acquisitions In circumstances where substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the asset is not considered a business and we account for the transaction as an asset acquisition. We recognize the assets acquired based on their relative fair value, which generally includes the transaction costs of the asset acquisition, and no gain or loss is recognized unless the fair value of noncash assets given as consideration differs from the assets’ carrying amounts. The form of consideration transferred may be cash, liabilities incurred, or equity interests issued. License Agreements We have entered and may continue to enter into license agreements to access and utilize certain technology. We evaluate if the license agreement results in the acquisition of an asset or a business and then determine if the acquired asset has the ability to generate revenues or is subject to regulatory approval. When regulatory approval is not required, we record the license as an asset and amortize it over the estimated economic life. When regulatory approval is required, we record the amount paid as a research and development expense.
Intangible assets and in-process research and development	Intangible assets Amortizable intangible assets include trade names, non-compete agreements, patent licensing agreements, favorable leases, developed technology, customer relationships, and rights to develop new technology acquired as part of business combinations. Customer relationships acquired through our business combinations in 2017 are amortized on an accelerated basis, utilizing free cash flows, over periods ranging from five ranging from five Property, Plant and Equipment. In-process research and development Intangible assets related to IPR&D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. During the fourth quarter and if business factors indicate more frequently, we perform an assessment of the qualitative factors affecting the fair value of our IPR&D projects. If the fair value exceeds the carrying value, there is no impairment. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of an asset to its carrying value, without consideration of any recoverability test.
Goodwill	Goodwill In accordance with ASC 350, Intangibles-Goodwill and Other , our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Under ASC 350, we perform annual impairment reviews of our goodwill balance during the fourth fiscal quarter or more frequently if business factors indicate. In testing for impairment, we compare the fair value of our reporting unit to its carrying value including the goodwill of that unit. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, we will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. The loss recognized cannot exceed the total amount of goodwill allocated to that reporting unit.
Leases	Leases Under ASC 842, Leases , we determine if an arrangement is a lease at inception. Operating leases are included in operating lease assets and operating lease obligations in our consolidated balance sheets. Finance leases are included in other assets and finance lease obligations in our consolidated balance sheets. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. We generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The operating lease asset also includes any lease payments made and is adjusted for lease incentives. Our lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that we will exercise that option. Leases with terms of 12 months or less are not recorded on our balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. We account for the lease and non-lease components of our operating right-of-use assets as a single lease component.
Property and equipment, net	Property and equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Manufacturing and Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life
Long-lived assets	Long-lived assetsWe review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value.
Fair value of financial instruments	Fair value of financial instrumentsOur financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, finance lease liabilities, and liabilities associated with business combinations. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our finance lease liabilities approximates their fair values. Liabilities associated with business combinations are recorded at their estimated fair value.
Revenue recognition	Deferred revenueWe record a contract liability when cash payments are received or due in advance of our performance related to one or more performance obligations. Revenue recognition We recognize revenue when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. All revenues are generated from contracts with customers. We utilize the following practical expedients and exemptions: • Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year or less, and • No adjustments to promised consideration were made for financing as we expect, at contract inception, that the period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less. Test revenue Test revenue is comprised of testing services and sales of distributed precision oncology products. The majority of our test revenue is generated from genetic testing, in addition to somatic testing for therapy selection and personalized cancer monitoring. These testing services provide analysis and associated interpretation of the sequencing of parts of the genome. Test orders are placed under signed requisitions or contractual agreements, and we often enter into contracts with insurance companies and institution customers that include pricing provisions under which such tests are billed. Billing terms are generally net 30 to 60 days. While the transaction price of diagnostic tests is originally established either via contract or pursuant to our standard list price, we often provide concessions for tests billed to insurance carriers, and therefore the transaction price for patient insurance-billed tests is considered to be variable and revenue is recognized based on an estimate of the consideration to which we will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. Making these estimates requires significant judgments based upon such factors as length of payer relationship, historical payment patterns, changes in contract provisions and insurance reimbursement policies. These judgments are reviewed each reporting period and updated as necessary. We look to transfer of control in assessing timing of recognition of revenue in connection with each performance obligation. In general, revenue in connection with the service portion of our diagnostic tests is recognized upon delivery of the underlying clinical report or when the report is made available on our web portal. Outstanding performance obligations pertaining to orders received but for which the underlying report has not been issued are generally satisfied within a 30-day period. We also generated test revenue through the sale of our distributed precision oncology products, which is comprised primarily of sales of our RUO kit and IVD product offerings for therapy selection. We recognized revenue on these sales once shipment had occurred. Product sales were recorded net of discounts and other deductions. Billing terms were generally net 30 days. As part of the strategic realignment, we exited these product offerings in fiscal year 2022. See Note 4, "Business combinations and dispositions" for additional information on the disposition of the RUO kit assets. See Note 5, "Goodwill and intangible assets" for additional information on the exit of the IVD product offering. Shipping and handling fees billed to customers are recorded as revenue in the consolidated statements of operations. The associated shipping and handling costs are recorded as cost of revenue. Other revenue Other revenue is primarily generated from collaboration agreements and genome network contracts as well as pharma development services provided to biopharmaceutical companies related to companion diagnostic development. We enter into collaboration and genome network contracts. Collaboration agreements provide customers with diagnostic testing and related data aggregation reporting services that are provided over the contract term. Collaboration revenue is recognized as the data and reporting services are delivered to the customer. Genome network offerings consist of subscription services related to a proprietary software platform designed to connect patients, clinicians, advocacy organizations, researchers and therapeutic developers to accelerate the understanding, diagnosis and treatment of hereditary disease. Such services are recognized on a straight-line basis over the subscription periods. Amounts due under collaboration and genome network agreements are typically billable on net 30-day terms. Contracts for companion diagnostic development consisted primarily of milestone-based payments along with annual fees and marked-up pass-through costs. The arrangements were treated as short-term contracts for revenue recognition purposes because they allow termination of the agreements by the customers with 30 to 120 days’ written notice without a termination penalty. Upon termination, customers were required to pay for the proportion of services provided under milestones that were in progress. We recognized revenue in an amount that reflected the consideration which we expect to receive in exchange for those goods or services. We recognized revenue as services are provided based on the progress made toward achieving the performance obligation, utilizing input methods, including labor hours expended and tests processed, that measure our progress toward the achievement of the milestone. Cost of revenue Cost of revenue reflects the aggregate costs incurred in delivering our products and services and includes expenses for materials and supplies, personnel-related costs, freight, costs for lab services and clinical trial support, equipment and infrastructure expenses and allocated overhead including rent, information technology costs, equipment depreciation, amortization of acquired intangibles, and utilities.
License agreements	Business combinations We apply ASC 805, Business Combinations , which requires recognition of assets acquired, liabilities assumed, and contingent consideration at their fair value on the acquisition date with subsequent changes recognized in earnings; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination and expensed as incurred; requires in-process research and development to be capitalized at fair value as an indefinite-lived intangible asset until completion or abandonment; and requires that changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period be recognized as a component of provision for taxes. We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. We base the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by our management, which consider our estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity , we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We remeasure this liability each reporting period and record changes in the fair value in change in fair value of contingent consideration in our consolidated statements of operations. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in our operating results from the date of acquisition. Asset acquisitions In circumstances where substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the asset is not considered a business and we account for the transaction as an asset acquisition. We recognize the assets acquired based on their relative fair value, which generally includes the transaction costs of the asset acquisition, and no gain or loss is recognized unless the fair value of noncash assets given as consideration differs from the assets’ carrying amounts. The form of consideration transferred may be cash, liabilities incurred, or equity interests issued. License Agreements We have entered and may continue to enter into license agreements to access and utilize certain technology. We evaluate if the license agreement results in the acquisition of an asset or a business and then determine if the acquired asset has the ability to generate revenues or is subject to regulatory approval. When regulatory approval is not required, we record the license as an asset and amortize it over the estimated economic life. When regulatory approval is required, we record the amount paid as a research and development expense.
Advertising	AdvertisingAdvertising expenses are expensed as incurred.
Stock-based compensation	Stock-based compensation We measure stock-based payment awards made to employees and directors based on the estimated fair values of the awards and recognize the compensation expense over the requisite service period. We use the Black-Scholes option-pricing model to estimate the fair value of stock option awards and ESPP purchases. The fair value of RSU awards with time-based vesting terms is based on the grant date share price. We grant PRSU awards to certain employees, which vest upon the achievement of certain performance conditions subject to the employees’ continued service relationship with us. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. We recognize such compensation expense on an accelerated vesting method. Stock-based compensation expense for awards without a performance condition is recognized using the straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We account for stock issued in connection with business combinations based on the fair value on the date of issuance.
Restructuring and other costs	Restructuring and other costs Restructuring and other costs are comprised of employee severance and benefits, asset impairments and losses on asset disposals, and other costs primarily related to implementing our strategic realignment. Employee separation costs are comprised of severance, other termination benefit costs, and stock-based compensation expense for the acceleration of stock awards related to workforce reductions. We recognize costs and liabilities associated with exit and disposal activities in accordance with ASC 420, Exit and Disposal Cost Obligations, and other costs and liabilities associated with postemployment nonretirement benefits in accordance with ASC 712, Postemployment Nonretirement Benefits . Liabilities are based on the estimate of fair value in the period the liabilities are incurred, with subsequent changes to the liability recognized as adjustments in the period of change. We recognize losses on asset disposals in accordance with ASC 360, Impairment or Disposal of Long-Lived Assets . Restructuring and other costs are recognized as an operating expense within the consolidated statements of operations and the related liabilities are recorded within accrued liabilities in the consolidated balance sheets.
Income taxes	Income taxes We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Significant judgment is required in determining the net valuation allowance which includes our evaluation of all available evidence including past operating results, estimates on future taxable income and acquisition-related tax assets and liabilities. We historically established a full valuation allowance against our deferred tax assets due to the uncertainty surrounding realization of such assets.
Comprehensive loss	Comprehensive loss Comprehensive loss is composed of two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity, but are excluded from net loss. Our other comprehensive income (loss) consists of unrealized gains or losses on investments in available-for-sale securities.
Net loss per share	Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities, consisting of preferred stock, options to purchase common stock, common stock warrants, shares of common stock pursuant to ESPP, common stock issuable in connection with our convertible senior notes, RSUs and PRSUs, are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per share because their effect would be antidilutive for all periods presented.
Recent accounting pronouncements	Recent accounting pronouncements We evaluate all Accounting Standards Updates ("ASUs") issued by the FASB for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our consolidated financial statements. Recently issued accounting pronouncements not yet adopted In October 2021, the FASB issued ASU 2021-08, Business Combinations ("Topic 805"): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments of this ASU require entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to all business combinations occurring after the date of adoption. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our consolidated financial statements. Recently adopted accounting pronouncements In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule significant customer, revenue as a percentage	Our revenue and accounts receivable from significant customers as a percentage of our total revenue and total accounts receivable was as follows: Revenue Accounts receivable Year Ended December 31, December 31, 2022 2021 2020 2022 2021 Medicare 14 % 15 % 19 % 16 % *
Schedule of restrictions on cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 257,489 $ 923,250 Restricted cash 10,030 10,275 Total cash, cash equivalents and restricted cash $ 267,519 $ 933,525
Schedule of cash, cash equivalents and restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 257,489 $ 923,250 Restricted cash 10,030 10,275 Total cash, cash equivalents and restricted cash $ 267,519 $ 933,525
Schedule of property and equipment, net	The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Manufacturing and Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life Property and equipment consisted of the following (in thousands): December 31, 2022 2021 Leasehold improvements $ 74,108 $ 31,159 Laboratory equipment 63,562 61,317 Computer equipment 13,712 15,452 Furniture and fixtures 1,428 2,130 Construction-in-progress 23,490 52,039 Other 2,996 925 Total property and equipment, gross 179,296 163,022 Accumulated depreciation and amortization (70,573) (48,308) Total property and equipment, net $ 108,723 $ 114,714

Revenue, accounts receivable _2

Revenue, accounts receivable and deferred revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue by payer category	The following tables present revenue disaggregated by customer and product offering by disease category (in thousands): Patient Institution Year Ended December 31, 2022 Insurance Direct Product: Oncology $ 208,239 $ 10,327 $ 89,922 $ 308,488 Women's health 70,571 18,082 7,127 95,780 Rare diseases 31,527 10,044 24,462 66,033 Data/services — — 46,002 46,002 Total revenue $ 310,337 $ 38,453 $ 167,513 $ 516,303 Patient Institution Year Ended December 31, 2021 Insurance Direct Product: Oncology $ 200,456 $ 11,341 $ 70,439 $ 282,236 Women's health 52,759 21,316 8,696 82,771 Rare diseases 23,701 9,011 24,504 57,216 Data/services — — 38,226 38,226 Total revenue $ 276,916 $ 41,668 $ 141,865 $ 460,449 Patient Institution Year Ended December 31, 2020 Insurance Direct Product: Oncology $ 142,552 $ 6,479 $ 25,868 $ 174,899 Women's health 25,050 12,684 6,404 44,138 Rare diseases 13,424 4,809 16,320 34,553 Data/services — — 26,008 26,008 Total revenue $ 181,026 $ 23,972 $ 74,600 $ 279,598
Schedule of change in estimate	In subsequent periods, we update our estimate of the amounts recognized for previously delivered tests resulting in the following increases to revenue and decreases to our net loss from operations and basic and diluted net loss per share (in millions, except per share data): Year Ended December 31, 2022 2021 2020 Revenue $ 2.8 $ 13.5 $ 4.4 Loss from operations $ (2.8) $ (13.5) $ (4.4) Net loss per share, basic and diluted $ (0.01) $ (0.06) $ (0.03)

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of goodwill	The changes in the carrying amounts of goodwill were as follows (in thousands): Balance as of December 31, 2021 $ 2,283,059 Impairment (2,283,059) Balance as of December 31, 2022 $ —
Schedule of intangible assets	The following table presents details of our acquired intangible assets as of December 31, 2022 (in thousands): December 31, 2022 Cost Accumulated Asset Disposals Net Weighted-Average Weighted-Average Customer relationships $ 41,515 $ (17,675) $ (359) $ 23,481 10.8 6.8 Developed technology 1,174,506 (183,133) (19,426) 971,947 10.8 9.3 Non-compete agreement 286 (286) — — — — Trade name 21,085 (3,964) — 17,121 12.0 9.8 Patent assets and licenses 495 (156) (339) — — — Right to develop new technology 19,359 (2,474) (16,885) — — — $ 1,257,246 $ (207,688) $ (37,009) $ 1,012,549 10.8 9.2 The following table presents details of our acquired intangible assets as of December 31, 2021 (in thousands): December 31, 2021 Cost Accumulated Net Weighted-Average Weighted-Average Customer relationships $ 41,515 $ (13,096) $ 28,419 10.8 7.8 Developed technology 662,106 (81,902) 580,204 10.2 9.1 Non-compete agreement 286 (286) — — — Trade name 21,085 (2,207) 18,878 12.0 10.8 Patent assets and licenses 495 (136) 359 15.0 10.9 Right to develop new technology 19,359 (1,613) 17,746 15.0 13.8 In-process research and development 542,388 — 542,388 n/a n/a $ 1,287,234 $ (99,240) $ 1,187,994 10.4 9.2
Schedule of intangible assets	The following table presents details of our acquired intangible assets as of December 31, 2022 (in thousands): December 31, 2022 Cost Accumulated Asset Disposals Net Weighted-Average Weighted-Average Customer relationships $ 41,515 $ (17,675) $ (359) $ 23,481 10.8 6.8 Developed technology 1,174,506 (183,133) (19,426) 971,947 10.8 9.3 Non-compete agreement 286 (286) — — — — Trade name 21,085 (3,964) — 17,121 12.0 9.8 Patent assets and licenses 495 (156) (339) — — — Right to develop new technology 19,359 (2,474) (16,885) — — — $ 1,257,246 $ (207,688) $ (37,009) $ 1,012,549 10.8 9.2 The following table presents details of our acquired intangible assets as of December 31, 2021 (in thousands): December 31, 2021 Cost Accumulated Net Weighted-Average Weighted-Average Customer relationships $ 41,515 $ (13,096) $ 28,419 10.8 7.8 Developed technology 662,106 (81,902) 580,204 10.2 9.1 Non-compete agreement 286 (286) — — — Trade name 21,085 (2,207) 18,878 12.0 10.8 Patent assets and licenses 495 (136) 359 15.0 10.9 Right to develop new technology 19,359 (1,613) 17,746 15.0 13.8 In-process research and development 542,388 — 542,388 n/a n/a $ 1,287,234 $ (99,240) $ 1,187,994 10.4 9.2
Summary of estimated future amortization expense of intangible assets with finite lives	The following table summarizes our estimated future amortization expense of intangible assets with finite lives as of December 31, 2022 (in thousands): 2023 $ 114,440 2024 114,162 2025 112,408 2026 112,374 2027 111,708 Thereafter 447,457 Total estimated future amortization expense $ 1,012,549

Balance sheet components (Table

Balance sheet components (Tables)	12 Months Ended
	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule of inventory	Inventory consisted of the following (in thousands): December 31, 2022 2021 Raw materials $ 29,992 $ 27,178 Work in progress 382 5,342 Finished goods 12 996 Total inventory $ 30,386 $ 33,516
Schedule of property and equipment, net	The estimated useful lives of property and equipment are as follows: Furniture and fixtures 7 years Automobiles 7 years Manufacturing and Laboratory equipment 5 years Computer equipment 3 years Software 3 years Leasehold improvements Shorter of lease term or estimated useful life Property and equipment consisted of the following (in thousands): December 31, 2022 2021 Leasehold improvements $ 74,108 $ 31,159 Laboratory equipment 63,562 61,317 Computer equipment 13,712 15,452 Furniture and fixtures 1,428 2,130 Construction-in-progress 23,490 52,039 Other 2,996 925 Total property and equipment, gross 179,296 163,022 Accumulated depreciation and amortization (70,573) (48,308) Total property and equipment, net $ 108,723 $ 114,714
Schedule of accrued liabilities	Accrued liabilities consisted of the following (in thousands): December 31, 2022 2021 Accrued compensation and related expenses $ 25,315 $ 35,877 Accrued expenses 23,628 32,136 Compensation and other liabilities associated with business combinations 5,335 11,622 Deferred revenue 4,814 9,431 Accrued interest 6,646 6,646 Accrued royalties 3,177 3,669 Other accrued liabilities 5,473 7,072 Total accrued liabilities $ 74,388 $ 106,453
Schedule of other long-term liabilities	Other long-term liabilities consisted of the following (in thousands): December 31, 2022 2021 Compensation and other liabilities associated with business combinations, non-current $ 769 $ 27,919 Deferred revenue, non-current 50 663 Other 3,956 9,215 Total other long-term liabilities $ 4,775 $ 37,797

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of financial instruments at fair value on a recurring basis	The following tables set forth the fair value of our financial instruments that were measured at fair value on a recurring basis (in thousands): December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 158,931 $ — $ — $ 158,931 $ 158,931 $ — $ — U.S. Treasury notes 193,685 1 (123) 193,563 193,563 — — U.S. government agency securities 96,006 55 (13) 96,048 — 96,048 — Total financial assets $ 448,622 $ 56 $ (136) $ 448,542 $ 352,494 $ 96,048 $ — Financial liabilities: Stock payable liability $ 744 $ — $ — $ 744 Contingent consideration 25 — — 25 Total financial liabilities $ 769 $ — $ — $ 769 December 31, 2022 Reported as: Cash equivalents $ 148,901 Restricted cash 10,030 Marketable securities 289,611 Total cash equivalents, restricted cash, and marketable securities $ 448,542 Other long-term liabilities $ 769 December 31, 2021 Amortized Gross Gross Estimated Level 1 Level 2 Level 3 Financial assets: Money market funds $ 913,990 $ — $ — $ 913,990 $ 913,990 $ — $ — U.S. Treasury notes 111,187 — (6) 111,181 111,181 — — U.S. government agency securities 10,941 — (1) 10,940 — 10,940 — Total financial assets $ 1,036,118 $ — $ (7) $ 1,036,111 $ 1,025,171 $ 10,940 $ — Financial liabilities: Stock payable liability $ 20,925 $ — $ — $ 20,925 Contingent consideration 1,875 — — 1,875 Total financial liabilities $ 22,800 $ — $ — $ 22,800 December 31, 2021 Reported as: Cash equivalents $ 903,715 Restricted cash 10,275 Marketable securities 122,121 Total cash equivalents, restricted cash, and marketable securities $ 1,036,111 Other long-term liabilities $ 22,800
Summary of stock payable liability and contingent consideration	The following tables include a rollforward of the stock payable liability and contingent consideration classified within Level 3 of the fair value hierarchy (in thousands): Stock Payable Liability Contingent Consideration Fair value at December 31, 2021 $ 20,925 $ 1,875 Change in fair value (15,906) (1,850) Settlements (4,275) — Fair value at December 31, 2022 $ 744 $ 25 Stock Payable Liability Contingent Consideration Fair value at December 31, 2020 $ 39,237 $ 796,639 Additions 31,522 — Change in fair value (25,196) (386,646) Settlements (24,638) (408,118) Fair value at December 31, 2021 $ 20,925 $ 1,875

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Components of lease cost	Supplemental information regarding our operating and finance leases were as follows: Year Ended December 31, 2022 2021 Weighted-average remaining lease term: Operating leases 8.9 years 9.0 years Finance leases 1.8 years 2.4 years Weighted-average discount rate: Operating leases 6.7 % 7.0 % Finance leases 7.3 % 7.2 % Cash payments included in the measurement of lease liabilities (in millions): Operating leases $ 22.4 $ 18.3 Finance leases $ 6.2 $ 2.9 The components of lease costs, which were included in cost of revenue, research and development, and general and administrative expenses in our consolidated statements of operations, were as follows (in thousands): Year Ended December 31, 2022 2021 2020 Operating lease costs $ 24,671 $ 21,151 $ 11,329 Finance lease costs: Amortization of right-of-use assets 4,778 3,488 2,084 Interest on lease liabilities 840 496 — Total lease costs $ 30,289 $ 25,135 $ 13,413
Schedule of future payments under operating leases	Future payments under operating and finance leases as of December 31, 2022 are as follows (in thousands): Operating leases Finance leases 2023 $ 23,691 $ 5,595 2024 28,308 3,344 2025 17,465 495 2026 23,989 — 2027 15,863 — Thereafter 91,177 — Future non-cancelable minimum lease payments 200,493 9,434 Less: interest (51,507) (533) Total lease liabilities 148,986 8,901 Less: current portion (14,600) (5,121) Lease obligations, net of current portion $ 134,386 $ 3,780
Schedule of future lease payments under finance leases	Future payments under operating and finance leases as of December 31, 2022 are as follows (in thousands): Operating leases Finance leases 2023 $ 23,691 $ 5,595 2024 28,308 3,344 2025 17,465 495 2026 23,989 — 2027 15,863 — Thereafter 91,177 — Future non-cancelable minimum lease payments 200,493 9,434 Less: interest (51,507) (533) Total lease liabilities 148,986 8,901 Less: current portion (14,600) (5,121) Lease obligations, net of current portion $ 134,386 $ 3,780
Components of debt	Our 2024 Notes and 2028 Notes (collectively, our "Convertible Senior Notes") consisted of the following (in thousands): December 31, 2022 2021 Outstanding principal $ 1,499,996 $ 1,499,996 Unamortized debt discount and issuance costs (29,213) (35,858) Net carrying amount, liability component $ 1,470,783 $ 1,464,138
Schedule of future payments under noncancelable unconditional purchase commitments	At December 31, 2022, our total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were as follows (in thousands): 2023 19,756 2024 11,065 2025 1,844 2026 500 2027 250 Total $ 33,415

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of convertible preferred and common stock	Shares of convertible preferred and common stock were as follows (in thousands): Year Ended December 31, 2022 2021 2020 Convertible preferred stock: Shares outstanding, beginning of period — 125 125 Conversion into common stock — (125) — Shares outstanding, end of period — — 125 Common stock: Shares outstanding, beginning of period 228,116 185,886 98,796 Common stock issued in private placement — — 16,320 Common stock issued in connection with public offering 2,429 8,932 24,005 Common stock issued on exercise of stock options, net 159 2,068 2,659 Common stock issued pursuant to vesting of RSUs 10,486 4,325 5,304 Common stock issued pursuant to exercises of warrants — 208 968 Common stock issued pursuant to employee stock purchase plan 2,231 654 671 Common stock issued pursuant to acquisitions 2,141 25,918 37,163 Common stock issued upon conversion of preferred stock — 125 — Shares outstanding, end of period 245,562 228,116 185,886

Stock incentive plans (Tables)

Stock incentive plans (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of activity under stock incentive plans	Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share data and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Balances at December 31, 2021 10,242 3,034 $ 11.98 5.5 $ 16,431 Additional shares reserved 9,125 — Options granted (1,121) 1,121 $ 3.03 Options cancelled 1,455 (1,455) $ 12.04 Options exercised — (159) $ 4.06 RSUs and PRSUs granted (12,508) — RSUs and PRSUs cancelled 5,432 — Balances at December 31, 2022 12,625 2,541 $ 8.49 6.6 $ 16 Options exercisable at December 31, 2022 1,384 $ 11.21 4.1 $ 16 Options vested and expected to vest at December 31, 2022 2,383 $ 8.84 6.1 $ 16
Summary of RSU activity	The following table summarizes RSU, including PRSU, activity (in thousands, except per share data): Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at December 31, 2021 16,247 $ 26.21 RSUs granted 11,622 $ 5.58 Time-based RSUs and PRSUs granted - variable 886 $ 2.47 RSUs vested (11,428) $ 23.03 RSUs cancelled (5,432) $ 16.67 Balance at December 31, 2022 11,895 $ 11.70
Schedule of assumptions used in determination of fair value of options	The fair value of share-based payments for stock options granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model based on the following assumptions: Year Ended December 31, 2022 2021 2020 Fair value of common stock $2.85 - $5.22 $34.90 $16.17 - $16.55 Expected term (in years) 6.0 6.0 6.0 Expected volatility 77.6% 73.5% 71.0% Risk-free interest rate 3.0% 1.1% 0.5% The fair value of the shares purchased pursuant to the ESPP was estimated using the following assumptions: Year Ended December 31, 2022 2021 2020 Expected term (in years) 0.5 0.5 0.5 Expected volatility 200.6% 66.1% 105.7% Risk-free interest rate 3.6% 0.0% 0.1%
Summary of stock based compensation expense related to stock options included in consolidated statements of operations	The following table summarizes stock-based compensation expense for the years ended December 31, 2022, 2021 and 2020, included in the consolidated statements of operations (in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenue $ 6,868 $ 12,033 $ 8,713 Research and development 113,843 92,407 91,762 Selling and marketing 12,897 15,641 14,418 General and administrative 35,378 59,994 43,854 Restructuring and other costs 30,318 — — Total stock-based compensation expense $ 199,304 $ 180,075 $ 158,747

Restructuring and other costs (

Restructuring and other costs (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following table summarizes the expenses related to our strategic realignment recognized in restructuring and other costs in our consolidated statement of operations (in thousands): Year Ended December 31, 2022 Employee severance and benefits $ 65,556 Impairments and losses on disposals of long-lived assets 60,507 Other restructuring costs 14,268 Total restructuring and other costs $ 140,331 The following table summarizes the changes in liabilities associated with our strategic realignment initiatives, including restructuring and other costs incurred and cash payments as of December 31, 2022 (in thousands): Employee severance and benefits Other restructuring costs Total Beginning balance $ — $ — $ — Accruals 35,237 7,405 42,642 Payments (32,974) (5,464) (38,438) Balance at December 31, 2022 $ 2,263 $ 1,941 $ 4,204

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of components of loss before income taxes by U.S. and foreign jurisdictions	The components of net loss before taxes by U.S. and foreign jurisdictions are as follows (in thousands): Year Ended December 31, 2022 2021 2020 United States $ 3,147,669 $ 414,657 $ 712,409 Foreign 3,528 1,206 1,861 Total $ 3,151,197 $ 415,863 $ 714,270
Schedule of components of the provision for income taxes	The components of the provision for income taxes are as follows (in thousands): Year Ended December 31, 2022 2021 2020 Current: Foreign 1,338 (2,069) (171) Total current benefit (expense) for income taxes 1,338 (2,069) (171) Deferred: Federal 22,368 28,348 94,279 State 19,512 8,809 17,730 Foreign 1,686 1,769 262 Total deferred benefit for income taxes 43,566 38,926 112,271 Total income tax benefit $ 44,904 $ 36,857 $ 112,100
Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense	The following table presents a reconciliation of the tax expense computed at the statutory federal rate and our tax expense for the periods presented: Year Ended December 31, 2022 2021 2020 U.S. federal taxes at statutory rate 21.0 % 21.0 % 21.0 % State taxes (net of federal benefit) 0.9 % 7.3 % 3.4 % Stock-based compensation (1.2) % (1.2) % (1.6) % Research and development credits 0.4 % 3.8 % 1.1 % Non-deductible expenses — % (0.9) % (0.7) % Foreign tax differential 0.1 % (0.1) % — % Acquisition contingent liabilities 0.1 % 18.5 % (0.8) % Non-deductible impairment expense (14.9) % — % — % Change in valuation allowance (4.9) % (39.5) % (6.7) % Total 1.5 % 8.9 % 15.7 %
Schedule of net deferred tax assets	The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 595,301 $ 530,663 Tax credits 49,615 36,188 R&D capitalization and amortization 72,358 6,202 Revenue recognition differences — 2,560 Leasing liabilities 36,986 34,403 Accruals and other 41,198 36,689 Gross deferred tax assets 795,458 646,705 Valuation allowance (542,900) (386,950) Total deferred tax assets 252,558 259,755 Deferred tax liabilities: Amortization and depreciation (216,899) (277,719) Revenue recognition differences (14,180) — Leasing assets (29,609) (33,732) Total deferred tax liabilities (260,688) (311,451) Net deferred tax liabilities $ (8,130) $ (51,696)
Schedule of reconciliation of gross unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year ended December 31, 2022 2021 2020 Unrecognized tax benefits, beginning of period $ 46,669 $ 21,965 $ 26,985 Gross increases—current period tax positions 14,161 18,165 8,368 Gross increases—prior period tax positions 243 6,539 53 Gross decreases—prior period tax positions (1,739) — (13,441) Unrecognized tax benefits, end of period $ 59,334 $ 46,669 $ 21,965

Net loss per share (Tables)

Net loss per share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data): Year ended December 31, 2022 2021 2020 Net loss $ (3,106,293) $ (379,006) $ (602,170) Shares used in computing net loss per share, basic and diluted 235,676 210,946 134,587 Net loss per share, basic and diluted $ (13.18) $ (1.80) $ (4.47)
Schedule of antidilutive securities excluded from computation of earnings per share	The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Year Ended December 31, 2022 2021 2020 Shares of common stock subject to outstanding options 3,113 4,069 6,878 Shares of common stock subject to outstanding warrants — 29 405 Shares of common stock subject to outstanding RSUs 17,874 9,146 5,590 Shares of common stock subject to outstanding PRSUs 148 737 1,658 Shares of common stock pursuant to ESPP 1,891 425 294 Shares of common stock underlying Series A convertible preferred stock — 93 125 Shares of common stock subject to Convertible Senior Notes conversion 38,403 38,403 8,371 Total shares of common stock equivalents 61,429 52,902 23,321

Geographic information (Tables)

Geographic information (Tables)	12 Months Ended
	Dec. 31, 2022
Segments, Geographical Areas [Abstract]
Schedule of revenue by geographic region	Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands): Year Ended December 31, 2022 2021 2020 United States $ 457,061 $ 404,013 $ 255,680 United Kingdom 9,185 5,485 2,185 Canada 8,779 7,553 4,529 Germany 5,445 8,102 2,299 Rest of world 35,833 35,296 14,905 Total revenue $ 516,303 $ 460,449 $ 279,598

Selected quarterly data (unau_2

Selected quarterly data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Schedule of selected quarterly data	The following tables summarize our quarterly financial information for 2022 and 2021 (in thousands, except per share amounts): Three Months Ended March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 Revenue $ 123,691 $ 136,622 $ 133,536 $ 122,454 Cost of revenue $ 97,116 $ 110,340 $ 116,956 $ 92,844 Loss from operations $ (213,233) $ (2,520,331) $ (289,951) $ (94,895) Net loss $ (181,859) $ (2,523,461) $ (301,156) $ (99,817) Net loss per share, basic and diluted (1) $ (0.80) $ (10.87) $ (1.27) $ (0.41) Three Months Ended March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 Revenue $ 103,621 $ 116,312 $ 114,395 $ 126,121 Cost of revenue $ 75,491 $ 89,331 $ 87,741 $ 96,106 (Loss) income from operations $ (112,364) $ 128,609 $ (193,312) $ (214,574) Net (loss) income $ (109,492) $ 133,786 $ (198,176) $ (205,124) Net (loss) income per share, basic (1) $ (0.56) $ 0.66 $ (0.91) $ (0.90) Net (loss) income per share, diluted (1) $ (0.56) $ 0.53 $ (0.91) $ (0.90) ___________________________________________________________________ (1) Net (loss) income per share is computed independently for each of the quarters presented. Therefore, the sum of quarterly net (loss) income per share information may not equal annual net (loss) income per share.

Organization and description _2

Organization and description of business (Details)	12 Months Ended
	Dec. 31, 2022 Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Summary of significant accoun_4

Summary of significant accounting policies - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible assets		10 years 9 months 18 days	10 years 4 months 24 days
Loss on disposal of property and equipment	$ (4,800)	$ 19,100	$ 0	$ 0
Advertising expense		5,900	20,200	11,400
Total stockholders’ equity		101,836	2,978,398	1,976,293
Accumulated deficit:
Summary Of Significant Accounting Policies [Line Items]
Total stockholders’ equity		(4,829,141)	(1,722,848)	(1,360,847)	$ (758,677)
Cumulative effect of accounting change | Accumulated deficit:
Summary Of Significant Accounting Policies [Line Items]
Total stockholders’ equity		$ 0	$ 17,005	$ 0
Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible assets		10 years 9 months 18 days	10 years 9 months 18 days
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible assets		5 years
Useful lives		3 years
Minimum | Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible assets		5 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible assets		12 years
Useful lives		7 years
Maximum | Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible assets		11 years

Summary of significant accoun_5

Summary of significant accounting policies - Schedule of significant customers, revenue as a percentage (Details) - Customer concentration risk - Medicare	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue
Product Information [Line Items]
Concentration risk	14%	15%	19%
Accounts receivable
Product Information [Line Items]
Concentration risk	16%

Summary of significant accoun_6

Summary of significant accounting policies - Schedule of cash, cash equivalents and restricted cash (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 257,489	$ 923,250
Restricted cash	10,030	10,275
Total cash, cash equivalents and restricted cash	$ 267,519	$ 933,525	$ 131,480	$ 157,572

Summary of significant accoun_7

Summary of significant accounting policies - Schedule of useful lives of property and equipment (Details)	12 Months Ended
	Dec. 31, 2022
Furniture and fixtures
Property and equipment
Useful lives	7 years
Automobiles
Property and equipment
Useful lives	7 years
Manufacturing and Laboratory equipment
Property and equipment
Useful lives	5 years
Computer equipment
Property and equipment
Useful lives	3 years
Software
Property and equipment
Useful lives	3 years

Revenue, accounts receivable _3

Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 122,454	$ 133,536	$ 136,622	$ 123,691	$ 126,121	$ 114,395	$ 116,312	$ 103,621	$ 516,303	$ 460,449	$ 279,598
Patient Insurance
Revenue:
Total revenue									310,337	276,916	181,026
Patient Direct
Revenue:
Total revenue									38,453	41,668	23,972
Institution
Revenue:
Total revenue									167,513	141,865	74,600
Oncology
Revenue:
Total revenue									308,488	282,236	174,899
Oncology | Patient Insurance
Revenue:
Total revenue									208,239	200,456	142,552
Oncology | Patient Direct
Revenue:
Total revenue									10,327	11,341	6,479
Oncology | Institution
Revenue:
Total revenue									89,922	70,439	25,868
Women's health
Revenue:
Total revenue									95,780	82,771	44,138
Women's health | Patient Insurance
Revenue:
Total revenue									70,571	52,759	25,050
Women's health | Patient Direct
Revenue:
Total revenue									18,082	21,316	12,684
Women's health | Institution
Revenue:
Total revenue									7,127	8,696	6,404
Rare diseases
Revenue:
Total revenue									66,033	57,216	34,553
Rare diseases | Patient Insurance
Revenue:
Total revenue									31,527	23,701	13,424
Rare diseases | Patient Direct
Revenue:
Total revenue									10,044	9,011	4,809
Rare diseases | Institution
Revenue:
Total revenue									24,462	24,504	16,320
Data/services
Revenue:
Total revenue									46,002	38,226	26,008
Data/services | Patient Insurance
Revenue:
Total revenue									0	0	0
Data/services | Patient Direct
Revenue:
Total revenue									0	0	0
Data/services | Institution
Revenue:
Total revenue									$ 46,002	$ 38,226	$ 26,008

Revenue, accounts receivable _4

Revenue, accounts receivable and deferred revenue - Schedule of change in estimate (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Change in Accounting Estimate [Line Items]
Total revenue	$ 122,454	$ 133,536	$ 136,622	$ 123,691	$ 126,121	$ 114,395	$ 116,312	$ 103,621	$ 516,303	$ 460,449	$ 279,598
Loss from operations	$ 94,895	$ 289,951	$ 2,520,331	$ 213,233	$ 214,574	$ 193,312	$ (128,609)	$ 112,364	$ 3,118,410	$ 391,641	$ 652,172
Net loss per share, basic (in dollars per share)	$ (0.41)	$ (1.27)	$ (10.87)	$ (0.80)	$ (0.90)	$ (0.91)	$ 0.66	$ (0.56)	$ (13.18)	$ (1.80)	$ (4.47)
Net loss per share, diluted (in dollars per share)	$ (0.41)	$ (1.27)	$ (10.87)	$ (0.80)	$ (0.90)	$ (0.91)	$ 0.53	$ (0.56)	$ (13.18)	$ (1.80)	$ (4.47)
Change in estimate of revenue recognition
Change in Accounting Estimate [Line Items]
Total revenue									$ 2,800	$ 13,500	$ 4,400
Loss from operations									$ (2,800)	$ (13,500)	$ (4,400)
Net loss per share, basic (in dollars per share)									$ (0.01)	$ (0.06)	$ (0.03)
Net loss per share, diluted (in dollars per share)									$ (0.01)	$ (0.06)	$ (0.03)

Revenue, accounts receivable _5

Revenue, accounts receivable and deferred revenue - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2021	Apr. 30, 2020	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Unbilled revenue			$ 1,300	$ 4,300
Deferred revenue, revenue recognized			4,700	2,900
Deferred revenue			4,814	9,431
Deferred revenue, non-current			50	663
Refund liability			$ 4,700	$ 1,200
Performance obligation timing			one to six months
CARES Act
Restructuring Cost and Reserve [Line Items]
Income received under the CARES Act	$ 2,300	$ 3,800

Business combinations and dis_2

Business combinations and dispositions - Genelex and YouScript (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Change in fair value of contingent consideration		$ (1,850)	$ (386,646)	$ 54,544
YouScript
Business Acquisition [Line Items]
Percentage of interest acquired	100%
Business combination, total purchase consideration	$ 52,700
Payments to acquired businesses, gross	$ 24,500
Change in fair value of contingent consideration			15,400
Genelex
Business Acquisition [Line Items]
Percentage of interest acquired	100%
Business combination, total purchase consideration	$ 13,200
Business acquisition, expected milestone duration	4 years
Contingent consideration	$ 2,000	$ 1,900	1,900
Genelex and YouScript
Business Acquisition [Line Items]
Hold-back consideration	$ 6,200		$ 3,500
Indemnification obligations | YouScript
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.5
Hold-back consideration	$ 1,400
Indemnification obligations | Genelex
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.1

Business combinations and dis_3

Business combinations and dispositions - ArcherDX (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended			3 Months Ended	12 Months Ended
	Jul. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Business Acquisition [Line Items]
Reduction in amount of contingent consideration liability					$ 1,850	$ 386,646	$ (54,544)
Stock-based compensation expense (income)					199,304	180,075	158,747
ArcherDX, Inc.
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)			30
Payments to acquired businesses, gross			$ 325,000
Reduction in purchase price				$ 1,200
Reduction in goodwill				1,200
Reduction in amount of contingent consideration liability				1,200
Stock-based compensation expense (income)					$ 0	41,800
ArcherDX, Inc. | ArcherDX Milestone Achievement Agreement
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	13.8	5	27
Payments to acquired businesses, gross	$ 3,300	$ 1,900
ArcherDX, Inc. | ArcherDX Milestone, one through four
Business Acquisition [Line Items]
Reduction in amount of contingent consideration liability						38,500
Share-based compensation expense, incremental cost						33,000
ArcherDX, Inc. | ArcherDX Final Milestone
Business Acquisition [Line Items]
Contingent consideration				$ 262,500			$ 287,700	$ 0
Stock-based compensation expense (income)						$ (29,700)

Business combinations and dis_4

Business combinations and dispositions - Disposition of RUO kit assets (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Net cash proceeds			$ 44,554	$ 0	$ 0
Gain on sale of RUO kit assets			47,354	$ 0	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | RUO Kit Business
Business Acquisition [Line Items]
Net cash proceeds	$ 44,500
Total cash consideration	48,100	$ 48,100	48,100
Up front consideration	$ 3,000	3,000	$ 3,000
Gain on sale of RUO kit assets		$ 47,400

Business combinations and dis_5

Business combinations and dispositions - One Codex (Details) - OneCodex shares in Millions, $ in Millions	1 Months Ended
	Feb. 28, 2021 USD ($) shares
Business Acquisition [Line Items]
Percentage of interest acquired	100%
Payments to acquired businesses, gross | $	$ 17.3
Business acquisition common stock issued (in shares)	1.4
Indemnification obligations
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.2

Business combinations and dis_6

Business combinations and dispositions - Disposition (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]		Restructuring and other costs
Disposal Group, Disposed of by Sale, Not Discontinued Operations | OneCodex
Business Acquisition [Line Items]
Loss on disposal	$ 19,800
Disposal Group, Disposed of by Sale, Not Discontinued Operations | OneCodex | Right to develop new technology
Business Acquisition [Line Items]
Intangible assets	19,400
Disposal Group, Disposed of by Sale, Not Discontinued Operations | OneCodex | Customer relationships
Business Acquisition [Line Items]
Intangible assets	$ 400

Business combinations and dis_7

Business combinations and dispositions - Genosity (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Business Acquisition [Line Items]
Total stock-based compensation expense		$ 199,304	$ 180,075	$ 158,747
Change in fair value of contingent consideration		(1,850)	(386,646)	$ 54,544
Genosity
Business Acquisition [Line Items]
Percentage of interest acquired	100%
Business combination, total purchase consideration	$ 196,000
Payments to acquired businesses, gross	$ 120,000
Business acquisition common stock issued (in shares)	1.9
Total stock-based compensation expense		$ 1,700	800
Contingent consideration	$ 7,000				$ 3,200
Change in fair value of contingent consideration			$ (3,800)
Genosity | RSUs
Business Acquisition [Line Items]
Value of units granted	$ 5,000

Business combinations and dis_8

Business combinations and dispositions - Ciitizen (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022
Business Acquisition [Line Items]
Change in fair value of contingent consideration		$ (1,850)	$ (386,646)	$ 54,544
Total stock-based compensation expense		199,304	180,075	$ 158,747
Ciitizen
Business Acquisition [Line Items]
Percentage of interest acquired	100%
Business combination, total purchase consideration	$ 308,300
Payments to acquired businesses, gross	$ 87,400
Business acquisition common stock issued (in shares)	6.3
Contingent consideration		400	12,100
Change in fair value of contingent consideration		(9,700)	(10,600)
Total stock-based compensation expense		87,200	$ 24,400
Stock-based compensation expense, accelerated cost		$ 29,000
Ciitizen | RSUs
Business Acquisition [Line Items]
Value of units granted					$ 246,900
Ciitizen | Indemnification obligations
Business Acquisition [Line Items]
Payments to acquired businesses, gross	$ 10,400
Business acquisition common stock issued (in shares)	0.8

Goodwill and intangible asset_2

Goodwill and intangible assets - Summary of goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022
Goodwill [Roll Forward]
Goodwill, beginning balance		$ 2,283,059
Impairment	$ (2,300,000)	(2,283,059)
Goodwill, ending balance		$ 0

Goodwill and intangible asset_3

Goodwill and intangible assets - Schedule of intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (207,688)	$ (99,240)
Asset Disposals			$ (37,009)
Total estimated future amortization expense	$ 1,012,549
Weighted-Average Useful Life (In Years)	10 years 9 months 18 days	10 years 4 months 24 days
Weighted-Average Estimated Remaining Useful Life (in Years)	9 years 2 months 12 days	9 years 2 months 12 days
Cost	$ 1,257,246	$ 1,287,234
Intangible assets, net	1,012,549	1,187,994
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	41,515	41,515
Accumulated Amortization	(17,675)	(13,096)
Asset Disposals			(359)
Total estimated future amortization expense	$ 23,481	$ 28,419
Weighted-Average Useful Life (In Years)	10 years 9 months 18 days	10 years 9 months 18 days
Weighted-Average Estimated Remaining Useful Life (in Years)	6 years 9 months 18 days	7 years 9 months 18 days
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,174,506	$ 662,106
Accumulated Amortization	(183,133)	(81,902)
Asset Disposals			(19,426)
Total estimated future amortization expense	$ 971,947	$ 580,204
Weighted-Average Useful Life (In Years)	10 years 9 months 18 days	10 years 2 months 12 days
Weighted-Average Estimated Remaining Useful Life (in Years)	9 years 3 months 18 days	9 years 1 month 6 days
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Cost	$ 286	$ 286
Accumulated Amortization	(286)	(286)
Asset Disposals			0
Total estimated future amortization expense	$ 0	$ 0
Weighted-Average Useful Life (In Years)	0 years	0 years
Weighted-Average Estimated Remaining Useful Life (in Years)	0 years	0 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Cost	$ 21,085	$ 21,085
Accumulated Amortization	(3,964)	(2,207)
Asset Disposals			0
Total estimated future amortization expense	$ 17,121	$ 18,878
Weighted-Average Useful Life (In Years)	12 years	12 years
Weighted-Average Estimated Remaining Useful Life (in Years)	9 years 9 months 18 days	10 years 9 months 18 days
Patent assets and licenses
Finite-Lived Intangible Assets [Line Items]
Cost	$ 495	$ 495
Accumulated Amortization	(156)	(136)
Asset Disposals			(339)
Total estimated future amortization expense	$ 0	$ 359
Weighted-Average Useful Life (In Years)	0 years	15 years
Weighted-Average Estimated Remaining Useful Life (in Years)	0 years	10 years 10 months 24 days
Right to develop new technology
Finite-Lived Intangible Assets [Line Items]
Cost	$ 19,359	$ 19,359
Accumulated Amortization	(2,474)	(1,613)
Asset Disposals			$ (16,885)
Total estimated future amortization expense	$ 0	$ 17,746
Weighted-Average Useful Life (In Years)	0 years	15 years
Weighted-Average Estimated Remaining Useful Life (in Years)	0 years	13 years 9 months 18 days
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development		$ 542,388

Goodwill and intangible asset_4

Goodwill and intangible assets - Narrative (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended			3 Months Ended	12 Months Ended
	Aug. 31, 2022	Dec. 31, 2021	Jul. 31, 2021	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Reclassification from indefinite lived to finite lived					$ 512,400
Impairment of intangible assets					108,400	$ 58,800	$ 26,600
Impairment				$ 2,300,000	2,283,059
Intangible asset impairment				30,000
Loss on disposal of property and equipment				$ 4,800	$ (19,100)	$ 0	$ 0
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]					Goodwill and IPR&D impairment
Stratify Genomics Inc.
Finite-Lived Intangible Assets [Line Items]
Equity interest issued or issuable, number of shares		1
Payments to acquire productive assets		$ 8,000
Deferred tax liabilities, other finite-lived assets					$ 8,700
Medneon LLC
Finite-Lived Intangible Assets [Line Items]
Payments to acquire productive assets			$ 12,900
Business combination, equity interest issued, (in shares)			0.4
Stratify Genomics Inc.
Finite-Lived Intangible Assets [Line Items]
Percentage of voting interests acquired		100%				100%
Business combination, total purchase consideration		$ 29,000
Consideration transferred, liabilities incurred		4,200
Recognized identifiable assets acquired and liabilities assumed, cash and equivalents		200				$ 200
Medneon LLC
Finite-Lived Intangible Assets [Line Items]
Business combination, total purchase consideration			$ 34,100
Percentage of interest acquired			100%
Business combination, liabilities incurred			$ 4,900
Fair value of cash and cash equivalents			200
Developed technology | Stratify Genomics Inc.
Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired		$ 37,500
Estimated useful life		8 years
Developed technology | Medneon LLC
Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired			$ 33,900
Estimated useful life			8 years
Right to develop new technology | ArcherDX, Inc.
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 16,900
Patents
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 300

Goodwill and intangible asset_5

Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 114,440
2024	114,162
2025	112,408
2026	112,374
2027	111,708
Thereafter	447,457
Total estimated future amortization expense	$ 1,012,549

Balance sheet components - Sche

Balance sheet components - Schedule of inventory (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Offsetting [Abstract]
Raw materials		$ 29,992	$ 27,178
Work in progress		382	5,342
Finished goods		12	996
Total inventory		30,386	33,516
Loss on disposal of property and equipment	$ (4,800)	$ 19,100	$ 0	$ 0

Balance sheet components - Prop

Balance sheet components - Property and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property and equipment
Property and equipment, gross	$ 179,296	$ 163,022
Accumulated depreciation and amortization	(70,573)	(48,308)
Total property and equipment, net	108,723	114,714
Depreciation	28,800	18,100	$ 10,500
Leasehold improvements
Property and equipment
Property and equipment, gross	74,108	31,159
Laboratory equipment
Property and equipment
Property and equipment, gross	63,562	61,317
Computer equipment
Property and equipment
Property and equipment, gross	13,712	15,452
Furniture and fixtures
Property and equipment
Property and equipment, gross	1,428	2,130
Construction-in-progress
Property and equipment
Property and equipment, gross	23,490	52,039
Other
Property and equipment
Property and equipment, gross	$ 2,996	$ 925

Balance sheet components - Accr

Balance sheet components - Accrued liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Accrued compensation and related expenses	$ 25,315	$ 35,877
Accrued expenses	23,628	32,136
Compensation and other liabilities associated with business combinations	5,335	11,622
Deferred revenue	4,814	9,431
Accrued interest	6,646	6,646
Accrued royalties	3,177	3,669
Other accrued liabilities	5,473	7,072
Accrued liabilities	$ 74,388	$ 106,453

Balance sheet components - Othe

Balance sheet components - Other long-term liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Compensation and other liabilities associated with business combinations, non-current	$ 769	$ 27,919
Deferred revenue, non-current	50	663
Other	3,956	9,215
Total other long-term liabilities	$ 4,775	$ 37,797

Balance sheet components - Addi

Balance sheet components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Offsetting [Abstract]
Inventory write-down		$ 14.3
Depreciation		28.8	$ 18.1	$ 10.5
Accelerated depreciation		6.1
Loss on disposal of property and equipment	$ (4.8)	$ 19.1	$ 0	$ 0

Fair value measurements - Finan

Fair value measurements - Financial instruments at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 448,622	$ 1,036,118
Gross Unrealized Gains	56	0
Gross Unrealized Losses	(136)	(7)
Financial assets	448,542	1,036,111
Cash equivalents	148,901	903,715
Restricted cash	10,030	10,275
Marketable securities	289,611	122,121
Other long-term liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	769	22,800
Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	448,542	1,036,111
Total financial liabilities	769	22,800
Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	352,494	1,025,171
Total financial liabilities	0	0
Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	96,048	10,940
Total financial liabilities	0	0
Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	0	0
Total financial liabilities	769	22,800
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	158,931	913,990
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Money market funds | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	158,931	913,990
Money market funds | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	158,931	913,990
Money market funds | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Money market funds | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
U.S. Treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	193,685	111,187
Gross Unrealized Gains	1	0
Gross Unrealized Losses	(123)	(6)
U.S. Treasury notes | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	193,563	111,181
U.S. Treasury notes | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	193,563	111,181
U.S. Treasury notes | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
U.S. Treasury notes | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	96,006	10,941
Gross Unrealized Gains	55	0
Gross Unrealized Losses	(13)	(1)
U.S. government agency securities | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	96,048	10,940
U.S. government agency securities | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
U.S. government agency securities | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	96,048	10,940
U.S. government agency securities | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Stock payable liability | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	744	20,925
Stock payable liability | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Stock payable liability | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Stock payable liability | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	744	20,925
Contingent consideration | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	25	1,875
Contingent consideration | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Contingent consideration | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Contingent consideration | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	$ 25	$ 1,875

Fair Value Measurement - Summar

Fair Value Measurement - Summary of stock payable liability and contingent consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in fair value	$ (15,900)	$ (25,200)	$ 37,500
Stock Payable Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	20,925	39,237
Change in fair value	(15,906)	(25,196)
Settlements	(4,275)	(24,638)
Additions		31,522
Fair value, ending balance	744	20,925	39,237
Contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	1,875	796,639
Change in fair value	(1,850)	(386,646)
Settlements	0	408,118
Additions		0
Fair value, ending balance	$ 25	$ 1,875	$ 796,639

Fair value measurements - Narra

Fair value measurements - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Option, Quantitative Disclosures [Line Items]
Transfers of assets and liabilities between Level 1, Level 2 and Level 3	$ 0	$ 0
Investments, interest income	6,800,000	6,900,000	$ 4,000,000
Total fair value of investments with unrealized losses	200,300,000
Change in fair value	$ 15,900,000	$ 25,200,000	$ (37,500,000)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income, net
Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Maturities period of available-for-sale securities	1 month
Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Maturities period of available-for-sale securities	5 months

Commitments and contingencies -

Commitments and contingencies - Leases (Details)	3 Months Ended
	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Operating Leased Assets [Line Items]
Finance lease, term of contract		3 years
Impairment charge	$ 4,400,000
Leasehold impairments	$ 2,300,000
Minimum
Operating Leased Assets [Line Items]
Remaining lease term		1 year
Minimum | Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow
Operating Leased Assets [Line Items]
Measurement input		100,000
Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow
Operating Leased Assets [Line Items]
Measurement input		0.0500
Maximum
Operating Leased Assets [Line Items]
Remaining lease term		12 years
Maximum | Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow
Operating Leased Assets [Line Items]
Measurement input		2,800,000
Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow
Operating Leased Assets [Line Items]
Measurement input		0.0850

Commitments and contingencies_2

Commitments and contingencies - Components of lease cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Weighted-average remaining lease term:
Operating leases	8 years 10 months 24 days	9 years
Finance leases	1 year 9 months 18 days	2 years 4 months 24 days
Weighted-average discount rate:
Operating leases	6.70%	7%
Finance leases	7.30%	7.20%
Cash payments included in the measurement of lease liabilities (in millions):
Operating leases	$ 22,400	$ 18,300
Finance leases	6,200	2,900
Lease Cost
Operating lease costs	24,671	21,151	$ 11,329
Amortization of right-of-use assets	4,778	3,488	2,084
Finance lease costs:	840	496	0
Total lease costs	$ 30,289	$ 25,135	$ 13,413

Commitments and contingencies_3

Commitments and contingencies - Schedule of future payments under operating and finance leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating leases
2023	$ 23,691
2024	28,308
2025	17,465
2026	23,989
2027	15,863
Thereafter	91,177
Future non-cancelable minimum lease payments	200,493
Less: interest	(51,507)
Total lease liabilities	148,986
Less: current portion	(14,600)	$ (12,359)
Lease obligations, net of current portion	134,386	124,369
Finance leases
2023	5,595
2024	3,344
2025	495
2026	0
2027	0
Thereafter	0
Future non-cancelable minimum lease payments	9,434
Less: interest	(533)
Total lease liabilities	8,901
Less: current portion	(5,121)	(4,156)
Lease obligations, net of current portion	3,780	$ 5,683
Expected sublease income, year one	900
Expected sublease income, year two	900
Expected sublease income, year three	$ 100

Commitments and contingencies_4

Commitments and contingencies - Debt financing (Details) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2019
Warrant
Long-term Purchase Commitment [Line Items]
Number of shares issued in transaction	0.7
Debt financing contingency
Long-term Purchase Commitment [Line Items]
Warrants issued (in shares)	1
Exercise price (in dollars per share)	$ 16.85
Convertible debt
Long-term Purchase Commitment [Line Items]
Debt discounts and issuance costs		$ 29,213,000	$ 35,858,000
2020 Term Loan | Secured Debt
Long-term Purchase Commitment [Line Items]
Aggregate principal amount	$ 135,000,000
Days prior to convertible debt extended maturity date	90 days
Fair value of term loan		130,000,000
Debt discounts and issuance costs	$ 32,800,000
2020 Term Loan | Secured Debt | Prior to third anniversary of closing date
Long-term Purchase Commitment [Line Items]
Prepayment fee	6%
2020 Term Loan | Secured Debt | After the third anniversary of closing date
Long-term Purchase Commitment [Line Items]
Prepayment fee	4%
2020 Term Loan | Secured Debt | LIBOR
Long-term Purchase Commitment [Line Items]
Floor rate	2%
Basis spread on variable rate	8.75%
Convertible Senior Notes Due 2024 | Convertible debt
Long-term Purchase Commitment [Line Items]
Aggregate principal amount					$ 350,000,000
Percent of debt extended	80%
Interest expense		30,800,000	24,900,000	$ 22,000,000
Loan and Security Agreement | Secured Debt
Long-term Purchase Commitment [Line Items]
Interest expense		$ 24,300,000	$ 23,700,000	$ 7,400,000

Commitments and contingencies_5

Commitments and contingencies - Convertible senior notes (Details)	1 Months Ended		12 Months Ended
	Apr. 30, 2021 USD ($) tradingDay $ / shares	Sep. 30, 2019 USD ($) tradingDay $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Amortization of debt issuance costs | $			$ 6,700,000	$ 5,300,000	$ 1,900,000
Convertible Senior Notes Due 2024 | Convertible debt
Debt Instrument [Line Items]
Aggregate principal amount | $		$ 350,000,000
Stated interest rate		2%
Conversion ratio		0.0336293
Conversion price (in dollars per share) | $ / shares		$ 29.74
Redemption price percentage		100%
Number of threshold trading days | tradingDay		20
Number of consecutive trading days | tradingDay		30
Threshold percentage of stock price trigger		130%
Threshold trading days immediately after five consecutive trading days | tradingDay		5
Maximum threshold percentage of stock price trigger		98%
Threshold trading days | tradingDay		30
Interest expense | $			30,800,000	$ 24,900,000	$ 22,000,000
Convertible Senior Notes Due 2028 | Convertible debt
Debt Instrument [Line Items]
Aggregate principal amount | $	$ 1,150,000,000
Stated interest rate	1.50%
Conversion ratio	0.0231589
Conversion price (in dollars per share) | $ / shares	$ 43.18
Redemption price percentage	100%
Number of threshold trading days | tradingDay	20
Number of consecutive trading days | tradingDay	30
Threshold percentage of stock price trigger	150%
Percent of par value	99%
Level 2
Debt Instrument [Line Items]
Fair value | $			261,600,000
Level 2 | Convertible Senior Notes Due 2028
Debt Instrument [Line Items]
Fair value | $			$ 576,700,000

Commitments and contingencies_6

Commitments and contingencies - Components of debt (Details) - Convertible debt - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Outstanding principal	$ 1,499,996	$ 1,499,996
Unamortized debt discount and issuance costs	(29,213)	(35,858)
Convertible senior notes
Debt Instrument [Line Items]
Net carrying amount, liability component	$ 1,470,783	$ 1,464,138

Commitments and contingencies_7

Commitments and contingencies - Other commitments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Other Commitments [Line Items]
Future non-cancelable minimum operating lease payments	$ 200,493
Service agreements and laboratory supplies
Other Commitments [Line Items]
2023	19,756
2024	11,065
2025	1,844
2026	500
2027	250
Total	$ 33,415

Commitments and contingencies_8

Commitments and contingencies - Contingencies (Details) - USD ($) $ in Millions	Sep. 30, 2022	Aug. 27, 2021
Gain Contingencies [Line Items]
Royalty rate	7%
Positive outcome of litigation
Gain Contingencies [Line Items]
Amount awarded from other party	$ 4	$ 4.7

Stockholders' equity - Schedule

Stockholders' equity - Schedule of convertible preferred and common stock (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Preferred Stock
Increase (Decrease) in Stockholders' Deficit
Shares outstanding, beginning of period	0	125	125
Common stock issued upon conversion of preferred stock (in shares)	0	125	0
Shares outstanding, end of period	0	0	125
Common stock
Increase (Decrease) in Stockholders' Deficit
Shares outstanding, beginning of period	228,116	185,886	98,796
Common stock issued upon conversion of preferred stock (in shares)	0	125	0
Common stock issued in private placement (in shares)	0	0	16,320
Common stock issued in connection with initial public offering, net of offering costs (in shares)	2,429	8,932	24,005
Options exercised (in shares)	159	2,068	2,659
Common stock issued pursuant to vesting of restricted stock units (in shares)	10,486	4,325	5,304
Common stock issued pursuant to exercises of warrants (in shares)	0	208	968
Common stock issued pursuant to employee stock purchase plan (in shares)	2,231	654	671
Common stock issued pursuant to acquisitions (in shares)	2,141	25,918	37,163
Shares outstanding, end of period	245,562	228,116	185,886

Stockholders' equity - Narrativ

Stockholders' equity - Narrative (Details) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	May 30, 2021 USD ($)	Jan. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares	Apr. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Aug. 31, 2017 $ / shares
Class of Stock [Line Items]
Common stock, authorized (in shares)					600,000,000	400,000,000
Common stock, par value (in dollars per share) | $ / shares					$ 0.0001	$ 0.0001
Preferred stock, par value (in dollars per share) | $ / shares					$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)					20,000,000	20,000,000
Preferred stock, outstanding (in shares)					0	0
Proceeds from issuance of common stock | $					$ 8,157	$ 23,767	$ 284,203
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, conversion ratio								1
Preferred stock, par value (in dollars per share) | $ / shares								$ 0.0001
Liquidation preference per share (in dollars per share) | $ / shares								$ 0.001
Preferred stock, authorized (in shares)					3,458,823	3,458,823
Common stock
Class of Stock [Line Items]
Common stock issued upon conversion of preferred stock (in shares)					0	125,000	0
Conversion of stock, shares issued (in shares)						124,913
Common stock issued during period (in shares)					2,429,000	8,932,000	24,005,000
Common stock issued in connection with public offering, net | $					$ 2	$ 4	$ 9
Preferred Stock
Class of Stock [Line Items]
Common stock issued upon conversion of preferred stock (in shares)					0	125,000	0
Preferred Stock | Convertible Preferred Stock
Class of Stock [Line Items]
Common stock issued upon conversion of preferred stock (in shares)						124,913
Underwritten public offering
Class of Stock [Line Items]
Proceeds from issuance of common stock | $		$ 460,000		$ 184,000
Net proceeds from issuance of underwritten public offering | $		$ 434,300		$ 173,000
Underwritten public offering | Common stock
Class of Stock [Line Items]
Number of shares issued in transaction		8,900,000		20,400,000
Shares issued price per share (in dollars per share) | $ / shares		$ 51.50		$ 9
Private placement | Common stock | ArcherDX, Inc.
Class of Stock [Line Items]
Shares issued price per share (in dollars per share) | $ / shares			$ 16.85
Net proceeds upon closing of private placement | $			$ 263,700
Common stock issued in connection with public offering, net | $			$ 275,000
2018 Sales Agreement | Cowen and Company, LLC
Class of Stock [Line Items]
Percentage of commission payable on gross proceeds	3%
2018 Sales Agreement | Cowen and Company, LLC | Common stock
Class of Stock [Line Items]
Proceeds from issuance of common stock | $					$ 10,000		$ 93,700
Number of shares issued in transaction					2,400,000		3,600,000
Shares issued price per share (in dollars per share) | $ / shares					$ 3.99		$ 26.33
Net proceeds upon closing of private placement | $					$ 9,700		$ 90,700
Maximum | 2018 Sales Agreement | Cowen and Company, LLC
Class of Stock [Line Items]
Proceeds from issuance of common stock | $	$ 400,000

Stock incentive plans - Additio

Stock incentive plans - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended			12 Months Ended
	Oct. 31, 2020	Jun. 30, 2020	Jan. 31, 2015	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock incentive plan
Common stock reserved for future issuance (in shares)				2,100
Stock-based compensation expense (income)				$ 199,304	$ 180,075	$ 158,747
Proceeds from stock plans				1,300
Unrecognized stock-based compensation				3,400
Unrecognized compensation expense, net of estimated forfeitures				$ 154,000
RSUs
Stock incentive plan
Vesting period				3 years
Vested stock units awarded (in shares)				11,428
Granted (in shares)				11,622
Weighted-average grant date fair value (in dollars per share)				$ 5.58
Shares of common stock subject to outstanding options
Stock incentive plan
Weighted-average grant date fair value (in dollars per share)					$ 34.90
Expected period to recognize on a straight-line basis				3 years 3 months 18 days
Employee Stock
Stock incentive plan
Purchase period				6 months
RSUs and PRSUs
Stock incentive plan
Expected period to recognize on a straight-line basis				1 year 6 months
Stock incentive plans
Stock incentive plan
Vesting period				4 years
Stock incentive plans | RSUs
Stock incentive plan
Vesting period				2 years
Stock incentive plans | RSUs | Executive Officer
Stock incentive plan
Vesting period				3 years
Stock incentive plans | Shares of common stock subject to outstanding options
Stock incentive plan
Weighted-average grant date fair value (in dollars per share)				$ 2.07	$ 22.46	$ 10.10
Total grant date fair value of options to purchase common stock vested				$ 1,800	$ 2,400	$ 2,800
Exercised, aggregate intrinsic value				$ 700	55,000	$ 104,400
Monthly vesting percentage				2.08%
Vesting rate upon anniversaries				25%
Stock incentive plans | RSUs and PRSUs
Stock incentive plan
Granted (in shares)				12,508
2019 Incentive Compensation Plan | PRSUs
Stock incentive plan
Vesting period		1 year
Vested stock units awarded (in shares)						800
Granted (in shares)		300
Value of units granted		$ 4,200
Common stock reserved for future issuance (in shares)		300
Stock-based compensation expense (income)				$ 2,700	$ 2,700	$ 700
2015 Employee Stock Purchase Plan
Stock incentive plan
Weighted-average grant date fair value (in dollars per share)				$ 2.34	$ 8.10	$ 10.98
Purchase price, percent of fair market value of common stock			85%
Management Incentive Plan | RSUs
Stock incentive plan
Vesting period				2 years
Minimum | Shares of common stock subject to outstanding options
Stock incentive plan
Weighted-average grant date fair value (in dollars per share)				$ 2.85		16.17
Minimum | 2010 Plan
Stock incentive plan
Employees holding voting rights of all classes of stock (as a percent)				10%
Exercise price of options on common stock (as a percent)				110%
Maximum | Shares of common stock subject to outstanding options
Stock incentive plan
Weighted-average grant date fair value (in dollars per share)				$ 5.22		$ 16.55
Maximum | 2010 Plan
Stock incentive plan
Term of options granted				10 years
ArcherDX, Inc.
Stock incentive plan
Stock-based compensation expense (income)				$ 0	$ 41,800
ArcherDX, Inc. | Stock incentive plans | Shares of common stock subject to outstanding options
Stock incentive plan
Number of options vested (in shares)	3,700

Stock incentive plans - Schedul

Stock incentive plans - Schedule of activity under stock incentive plans (Details) - Stock incentive plans - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Stock Option
Activity under the plan
Shares available for grant, beginning balance (in shares)	10,242
Stock options outstanding, beginning balance (in shares)	3,034
Additional shares reserved (in shares)	9,125
Options granted (in shares)	(1,121)
Option cancelled (in shares)	(1,455)
Options exercised (in shares)	(159)
Shares available for grant, ending balance (in shares)	12,625	10,242
Stock options outstanding, ending balance (in shares)	2,541	3,034
Exercisable (in shares)	1,384
Number of options (in shares)	2,383
Weighted-Average Exercise Price Per Share
Balance at the beginning of the period (in dollars per share)	$ 11.98
Options granted (in dollars per share)	3.03
Options cancelled (in dollars per share)	12.04
Options exercised (in dollars per share)	4.06
Balance at the end of the period (in dollars per share)	8.49	$ 11.98
Exercisable, weighted-average exercise price (in dollars per share)	11.21
Weighted-average exercise price (in dollars per share)	$ 8.84
Additional information
Weighted-average remaining contractual life	6 years 7 months 6 days	5 years 6 months
Exercisable, weighted-average remaining contractual life	4 years 1 month 6 days
Weighted-average remaining contractual life	6 years 1 month 6 days
Aggregate intrinsic value	$ 16	$ 16,431
Exercisable, aggregate intrinsic value	16
Aggregate intrinsic value	$ 16
RSUs and PRSUs
Activity under the plan
Options granted (in shares)	(12,508)
Units cancelled (in shares)	5,432

Stock incentive plans - Summary

Stock incentive plans - Summary of RSU activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
RSUs
Number of Shares
Balance at the beginning of the period (in shares) | shares	16,247
RSUs granted (in shares) | shares	11,622
RSUs vested (in shares) | shares	(11,428)
RSUs cancelled (in shares) | shares	(5,432)
Balance at the end of the period (in shares) | shares	11,895
Weighted-Average Grant Date Fair Value Per Share
Balance at the beginning of the period (in dollars per share) | $ / shares	$ 26.21
Granted (in dollars per share) | $ / shares	5.58
Vested (in dollars per share) | $ / shares	23.03
Canceled (in dollars per share) | $ / shares	16.67
Balance at the end of the period (in dollars per share) | $ / shares	$ 11.70
Time-based RSUs and PRSUs
Number of Shares
Time-based RSUs and PRSUs granted - variable (in shares) | shares	886
Weighted-Average Grant Date Fair Value Per Share
Granted (in dollars per share) | $ / shares	$ 2.47

Stock incentive plans - Sched_2

Stock incentive plans - Schedule of assumptions used in determination of fair value of options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Stock Option
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted-average grant date fair value (in dollars per share)		$ 34.90
Expected term (in years)	6 years	6 years	6 years
Expected volatility	77.60%	73.50%	71%
Risk-free interest rate	3%	1.10%	0.50%
Employee Stock Option | Minimum
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 2.85		$ 16.17
Employee Stock Option | Maximum
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted-average grant date fair value (in dollars per share)	5.22		16.55
2015 Employee Stock Purchase Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 2.34	$ 8.10	$ 10.98
Expected term (in years)	6 months	6 months	6 months
Expected volatility	200.60%	66.10%	105.70%
Risk-free interest rate	3.60%	0%	0.10%

Stock incentive plans - Stock-b

Stock incentive plans - Stock-based compensation expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock-based compensation
Total stock-based compensation expense	$ 199,304	$ 180,075	$ 158,747
Cost of revenue
Stock-based compensation
Total stock-based compensation expense	6,868	12,033	8,713
Research and development
Stock-based compensation
Total stock-based compensation expense	113,843	92,407	91,762
Selling and marketing
Stock-based compensation
Total stock-based compensation expense	12,897	15,641	14,418
General and administrative
Stock-based compensation
Total stock-based compensation expense	35,378	59,994	43,854
Restructuring and other costs
Stock-based compensation
Total stock-based compensation expense	$ 30,318	$ 0	$ 0

Restructuring and other costs -

Restructuring and other costs - Additional Information (Details) $ in Millions	Jul. 18, 2022 employee	Dec. 31, 2022 USD ($)
Restructuring Cost and Reserve [Line Items]
Expected employee reduction | employee	1,000
Employee severance and benefits
Restructuring Cost and Reserve [Line Items]
Expected remaining restructuring cost		$ 1.2
Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Expected remaining restructuring cost		$ 3.5

Restructuring and other costs_2

Restructuring and other costs - Summary of expenses related to realignment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring and Related Activities [Abstract]
Employee severance and benefits	$ 65,556
Impairments and losses on disposals of long-lived assets	60,507	$ 0	$ 0
Other restructuring costs	14,268
Total restructuring and other costs	$ 140,331

Restructuring and other costs_3

Restructuring and other costs - Summary of changes in liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	$ 0
Accruals	42,642
Payments	(38,438)
Restructuring reserve, ending balance	4,204
Employee severance and benefits
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	0
Accruals	35,237
Payments	(32,974)
Restructuring reserve, ending balance	2,263
Other restructuring costs
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	0
Accruals	7,405
Payments	(5,464)
Restructuring reserve, ending balance	$ 1,941

Income taxes - Schedule of comp

Income taxes - Schedule of components of loss before income taxes by U.S. and foreign jurisdictions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
United States	$ 3,147,669	$ 414,657	$ 712,409
Foreign	3,528	1,206	1,861
Total	$ 3,151,197	$ 415,863	$ 714,270

Income taxes - Schedule of co_2

Income taxes - Schedule of components of the provision for income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Foreign	$ 1,338	$ (2,069)	$ (171)
Total current benefit (expense) for income taxes	1,338	(2,069)	(171)
Deferred:
Federal	22,368	28,348	94,279
State	19,512	8,809	17,730
Foreign	1,686	1,769	262
Total deferred benefit for income taxes	43,566	38,926	112,271
Total income tax benefit	$ 44,904	$ 36,857	$ 112,100

Income taxes - Schedule of reco

Income taxes - Schedule of reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of the tax expense computed at the statutory federal rate and Company's tax expense
U.S. federal taxes at statutory rate	21%	21%	21%
State taxes (net of federal benefit)	0.90%	7.30%	3.40%
Stock-based compensation	(1.20%)	(1.20%)	(1.60%)
Research and development credits	0.40%	3.80%	1.10%
Non-deductible expenses	0%	(0.90%)	(0.70%)
Foreign tax differential	0.10%	(0.10%)	0%
Acquisition contingent liabilities	0.10%	18.50%	(0.80%)
Non-deductible impairment expense	(14.90%)	0%	0%
Change in valuation allowance	(4.90%)	(39.50%)	(6.70%)
Total	1.50%	8.90%	15.70%

Income taxes - Schedule of net

Income taxes - Schedule of net deferred tax assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 595,301	$ 530,663
Tax credits	49,615	36,188
R&D capitalization and amortization	72,358	6,202
Revenue recognition differences	0	2,560
Leasing liabilities	36,986	34,403
Accruals and other	41,198	36,689
Gross deferred tax assets	795,458	646,705
Valuation allowance	(542,900)	(386,950)
Total deferred tax assets	252,558	259,755
Deferred tax liabilities:
Amortization and depreciation	(216,899)	(277,719)
Revenue recognition differences	(14,180)	0
Leasing assets	(29,609)	(33,732)
Total deferred tax liabilities	(260,688)	(311,451)
Net deferred tax liabilities	$ (8,130)	$ (51,696)

Income taxes - Narrative (Detai

Income taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Valuation allowance	$ 41,900
Increase in valuation allowance	155,900	$ 177,600	$ 64,000
Unrecognized tax benefits	59,334	46,669	21,965	$ 26,985
Unrecognized tax benefits that would impact effective tax rate	200
Gross decreases—prior period tax positions	(1,739)	$ 0	$ (13,441)
Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 2,400,000
Number of tax years open for examination	3 years
Federal | Research and development
Income Tax Contingency [Line Items]
Tax credit carryforwards	$ 79,900
State
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 1,500,000
Number of tax years open for examination	4 years
State | Research and development
Income Tax Contingency [Line Items]
Tax credit carryforwards	$ 32,200
Begins to expire 2030 | Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	285,000
No expiration date | Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 2,100,000

Income taxes - Schedule of re_2

Income taxes - Schedule of reconciliation of unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, beginning of period	$ 46,669	$ 21,965	$ 26,985
Gross increases—current period tax positions	14,161	18,165	8,368
Gross increases—prior period tax positions	243	6,539	53
Gross decreases—prior period tax positions	(1,739)	0	(13,441)
Unrecognized tax benefits, end of period	$ 59,334	$ 46,669	$ 21,965

Net loss per share - Schedule o

Net loss per share - Schedule of earnings per share, basic and diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss	$ (99,817)	$ (301,156)	$ (2,523,461)	$ (181,859)	$ (205,124)	$ (198,176)	$ 133,786	$ (109,492)	$ (3,106,293)	$ (379,006)	$ (602,170)
Shares used in computing net loss per share, basic (in shares)									235,676,000	210,946,000	134,587,000
Shares used in computing net loss per share, diluted (in shares)									235,676,000	210,946,000	134,587,000
Net loss per share, basic (in dollars per share)									$ (13.18)	$ (1.80)	$ (4.47)
Net loss per share, diluted (in dollars per share)									$ (13.18)	$ (1.80)	$ (4.47)

Net loss per share - Schedule_2

Net loss per share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	61,429	52,902	23,321
Shares of common stock subject to outstanding options
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,113	4,069	6,878
Shares of common stock subject to outstanding warrants
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	29	405
Shares of common stock subject to outstanding RSUs
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	17,874	9,146	5,590
Shares of common stock subject to outstanding PRSUs
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	148	737	1,658
Shares of common stock pursuant to ESPP
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,891	425	294
Shares of common stock underlying Series A convertible preferred stock
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	93	125
Shares of common stock subject to Convertible Senior Notes conversion
Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	38,403	38,403	8,371

Geographic information (Details

Geographic information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Geographic information
Total revenue	$ 122,454	$ 133,536	$ 136,622	$ 123,691	$ 126,121	$ 114,395	$ 116,312	$ 103,621	$ 516,303	$ 460,449	$ 279,598
United States
Geographic information
Total revenue									457,061	404,013	255,680
United Kingdom
Geographic information
Total revenue									9,185	5,485	2,185
Canada
Geographic information
Total revenue									8,779	7,553	4,529
Germany
Geographic information
Total revenue									5,445	8,102	2,299
Rest of world
Geographic information
Total revenue									$ 35,833	$ 35,296	$ 14,905

Selected quarterly data (unau_3

Selected quarterly data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$ 122,454	$ 133,536	$ 136,622	$ 123,691	$ 126,121	$ 114,395	$ 116,312	$ 103,621	$ 516,303	$ 460,449	$ 279,598
Cost of revenue	92,844	116,956	110,340	97,116	96,106	87,741	89,331	75,491	417,256	348,669	198,275
Loss from operations	(94,895)	(289,951)	(2,520,331)	(213,233)	(214,574)	(193,312)	128,609	(112,364)	(3,118,410)	(391,641)	(652,172)
Net loss	$ (99,817)	$ (301,156)	$ (2,523,461)	$ (181,859)	$ (205,124)	$ (198,176)	$ 133,786	$ (109,492)	$ (3,106,293)	$ (379,006)	$ (602,170)
Net loss per share, basic (in dollars per share)	$ (0.41)	$ (1.27)	$ (10.87)	$ (0.80)	$ (0.90)	$ (0.91)	$ 0.66	$ (0.56)	$ (13.18)	$ (1.80)	$ (4.47)
Net loss per share, diluted (in dollars per share)	$ (0.41)	$ (1.27)	$ (10.87)	$ (0.80)	$ (0.90)	$ (0.91)	$ 0.53	$ (0.56)	$ (13.18)	$ (1.80)	$ (4.47)

Subsequent events (Details)

Subsequent events (Details) - USD ($)			3 Months Ended	12 Months Ended
	Feb. 28, 2023	Feb. 07, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 30, 2021	Oct. 31, 2020	Sep. 30, 2019
Subsequent Event [Line Items]
Interest paid				$ 40,504,000	$ 31,400,000	$ 12,130,000
2020 Term Loan | Secured Debt
Subsequent Event [Line Items]
Aggregate principal amount								$ 135,000,000
Convertible Senior Notes Due 2024 | Convertible debt
Subsequent Event [Line Items]
Aggregate principal amount									$ 350,000,000
Stated interest rate									2%
Convertible Senior Notes Due 2028 | Convertible debt
Subsequent Event [Line Items]
Aggregate principal amount							$ 1,150,000,000
Stated interest rate							1.50%
Subsequent event
Subsequent Event [Line Items]
Common stock issued pursuant to securities purchase agreement	$ 30,600,000
Subsequent event | 2020 Term Loan | Secured Debt
Subsequent Event [Line Items]
Repayment of term loan		$ 53,700,000
Prepaid amount	85,000,000	50,000,000
Debt extinguishment costs	5,100,000	$ 3,000,000
Interest paid	1,900,000
Subsequent event | Convertible Senior Notes Due 2024 | Convertible debt
Subsequent Event [Line Items]
Aggregate principal amount	305,700,000
Subsequent event | Convertible Senior Notes Due 2028 | Convertible debt
Subsequent Event [Line Items]
Aggregate principal amount	$ 275,300,000
Stated interest rate	4.50%
Subsequent event | Convertible Senior Notes Due 2028 | Convertible debt | Forecast
Subsequent Event [Line Items]
Proceeds from issuance of debt			$ 30,000,000